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ABSTRACT 
GRIM-19 is a gene that encodes a 16-kDa protein originally identified as a critical 
regulatory protein for interferon (INF)-ß and retinoic acid (RA)-induced cell death. It was 
also demonstrated that GRIM- 19 is involved in mitochondrial metabolism, as an integrant 
component of complex I of the mitochondrial respiratory chain (MRC). GRIM-19 appears, 
therefore, as a dual function protein involved in cell death and mitochondrial metabolism. 
Moreover, GRIM-19 downregulation was observed in all subtypes of renal cell carcinomas 
(RCC), particularly in clear cell renal cell carcinoma (ccRCC), in contrast with thyroid 
tumors in which GRIM-19 downregulation is specifically associated with oncocytic tumors 
(Hürthle cell tumors, mitochondrion-rich), suggesting a role for GRIM-19 in tumorigenesis. 
As GRIM-19 binds and inhibits the signal transducer and activator of transcription-3 
(STAT3), which has been shown to be activated and playing a major role in several human 
tumors, it is tempting to advance that GRIM-19 may function as a tumor suppressor in those 
tumors. Recently it was reported that STAT3 is located in mitochondria and it appears to be 
involved in the regulation of mitochondrial metabolism. Thus, it is necessary to clarify if 
and how the interaction between GRIM-19 and STAT3 proteins interferes with main 
function of mitochondria: energy production and cell death regulation. 
The aim of this work was to investigate the potential role of GRIM-19 as a tumor 
suppressor gene by studying its interaction with STAT3 protein and by clarifying the 
mechanism (s) responsible for its downregulation and lack of GRIM-19 expression in RCC, 
particularly in ccRCC. 
Blocking GRIM-19 expression using a specific short hairpin RNAs (shRNA) in 
ccRCC derived cell lines (Caki-2 and 786-O) and in a human embryonic kidney cell line 
(HEK 293), we observed that GRIM-19 downregulation leads to an increase of 
phosphorylated STAT3, thereby increasing STAT3 activity in tumoral cells but not in non 
tumoral cells. Our data suggests that GRIM-19 expression, in RCC, is regulated through a 
repressive mechanism by transcription factors. We hypothesize a model of how GRIM-19 
and STAT3 interaction could be linked with their dual functions and their cellular 
localization. GRIM-19 and p-STAT3Ser727 interaction in mitochondria may have a 
determinant role in ccRCC tumorigenesis but it needs further investigations.  
Overall, we conclude that GRIM-19 and STAT3 interaction has a relevant role in 
renal tumorigenesis. In contrast with thyroid, GRIM-19 may have a broader role in kidney 
tumorigenesis playing a major role in cell morphology and cell metabolic remodeling. 
Key words: Mitochondrial protein; GRIM-19; STAT3; Tumorigenesis; Clear cell renal cell carcinoma.

  
 
iv 
RESUMO  
    O GRIM-19 é um gene que codifica uma proteína de 16kDa originalmente 
identificada como sendo importante na regulação da morte celular induzida por interferão e 
ácido retinóico. Posteriormente foi também demonstrado que a proteína GRIM-19 é parte 
integrante do complexo I da cadeia respiratória mitocondrial (CRM) participando no 
processo da fosforilação oxidativa. Deste modo, a proteína GRIM-19 parece exercer uma 
dupla função na célula, estando envolvida na regulação da morte celular e no metabolismo 
mitocondrial. Foi observada uma subexpressão em todos os sub-tipos de carcinomas de 
células renais (CCR), nomeadamente no carcinoma de células claras renais (CCCR), 
contrariamente aos tumores de tireóide, onde a subexpressão da proteína GRIM-19 está 
especialmente associada a tumores de tireóide com características oncocíticas (com células 
Hürthle -caracterizadas pela presença de um elevado número de mitocôndrias), sugerindo 
assim um papel do gene/da proteína GRIM-19 na tumorigénese. 
         Uma vez que a proteína GRIM-19 se liga e inibe o transdutor de sinal e activador de 
transcrição-3 (STAT3), o qual está ativado em muitos tumores humanos, é possível que o 
GRIM-19 funcione como gene supressor tumoral em tumores nos quais a proteína STAT3 
desempenhe um papel importante. Por outro lado, foi recentemente descrito que a proteína 
STAT3 se pode também localizar na mitocôndria regulando a atividade dos complexos I e 
II da CRM e por conseguinte, o metabolismo celular. Assim, é necessário esclarecer se e 
como a interação destas duas proteínas interfere nas principais funções da mitocôndria: 
produção de energia e regulação da morte celular.  
O principal objectivo deste trabalho foi investigar o papel do GRIM-19 como 
potencial gene supressor tumoral, nomeadamente através da sua interação com a proteína 
STAT3 na tumorigénese renal e ao mesmo tempo, identificar e perceber quais os 
mecanismos responsáveis pela sua subexpressão e/ou ausência de expressão da proteína 
GRIM-19 em CCR, particularmente em CCCR.  
Bloqueando a expressão de GRIM-19 usando um “short hairpin” RNAs (shRNA) 
específico em linhas celulares derivadas de CCCR (Caki-2 e 786-O) e numa linha renal 
embrionária humana (HEK-293), observámos que a subexpressão da proteína GRIM-19 tem 
efeitos distintos em células tumorais e não-tumorais, quer em termos de remodelação 
metabólica quer quanto à forma como a proteína GRIM-19 interage com a proteína STAT3. 
Nos clones de 786-O shGRIM-19 a subexpressão da proteína GRIM-19 levou a uma 
alteração metabólica, tornando as células mais glicolíticas (maior consumo de glucose e 
maior produção de lactato e aumento de expressão da enzima glicolítica HK II e do 
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transportador de glucose GLUT1). Contudo, nas linhas celulares HEK não observámos esse 
efeito, mas sim menor expressão das proteínas glicolíticas.  
Através de ensaios de imunofluorescência e avaliação do potencial de membrana (JC-
1), observámos que a subexpressão da proteína GRIM-19 implica uma reorganização ao 
nível do citoesqueleto da célula, assim como da sua rede mitocondrial; também se 
confirmou que a subexpressão da proteína GRIM-19 provoca um decréscimo da actividade 
mitocondrial a nível do complexo I da CRM. Assim, a proteína GRIM-19 parece ter um 
papel mais abrangente na tumorigénese renal.    
Os resultados deste trabalho permitiu-nos também propor um possível mecanismo 
pelo qual a expressão da proteína GRIM-19 é regulada em CCR. Inicialmente, verificámos 
que as linhas renais tumorais 786-O e Caki-2 tinham uma expressão distinta da proteína 
GRIM-19, a qual não se devia a mutações genéticas. Para além disso, realizámos Real-time 
PCR para fazer uma quantificação relativa de GRIM-19 mRNA, que mostrou também não 
haver qualquer tipo de alteração a nível transcripcional. Contrariamente, ao “alternative 
splicing” descrito por outros autores, obtivémos um transcripto normal do exão 1ao 5 com 
cerca de 402bp. Tendo em conta muitos estudos que identificaram que, em tumores de 
células renais, a maioria dos genes supressores tumorais estão subexpressos devido à 
hipermetilação do promotor, iniciámos uma análise do estado de metilação da provável 
região do promotor do gene GRIM-19 nas linhas Caki-2 e 786-O. Verificámos que a linha 
celular 786-O, a que tinha menor expressão da proteína GRIM-19, era a tinha uma fracção 
mais hipermetilada. Procedemos então a um tratamento de desmetilação com 5Aza-dC para 
ver se ocorria um aumento de expressão da proteína GRIM-19. Surpreendentemente, por 
Real-Time PCR, confirmou-se a análise prévia por Western blot, que mostrou que a linha 
celular 786-O não sofreu alterações mas que a linha celular Caki-2 sofreu um decréscimo de 
cerca de 50% de expressão do GRIM-19.Ao mesmo tempo, também por Real-Time PCR, 
observou-se um aumento muito significativo do STAT3 mRNA, particularmente na linha 
celular 786-O. Adicionalmente, procedemos a uma análise de um fragmento de ilhas CpG 
para tentar identificar quantas e quais as ilhas CpG que estavam metiladas. Verificamos que 
as linhas celulares tinham padrões de metilação distintos. Apesar de não se ter usado um 
método quantitativo do grau de metilação, poderemos afirmar que a linha celular Caki-2 
mostrou evidências de estar mais metilada e que com o tratamento de desmetilação algumas 
ilhas identificadas mostram uma perda significativa desse padrão de metilação. 
Todos estes resultados demonstram que a subexpressão da proteína/gene GRIM-19 
em CCCR estará associada à hipermetilação do seu promotor (verificado por dois métodos 
diferentes). Sugerimos ainda que a transcrição do gene GRIM-19 poderá estar sob a 
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regulação de um mecanismo de repressão por acção de factores de transcrição, dado que, na 
região do promotor estudada, existem locais de ligação de vários factores de transcrição, 
incluindo o STAT3. 
 Este trabalho permitiu-nos também idealizar um modelo de interacção entre as 
proteínas GRIM-19 e STAT3 e como esta pode estar relacionada com a dupla função das 
mesmas e a sua localização celular. Serão necessários mais ensaios para confirmar a co-
localização destas proteínas na mitocôndria e a sua interacção, bem como para saber se a 
presumível localização do p-STAT3Ser727 na mitocôndria, observada aquando de um 
ensaio de fraccionamento celular, poderá ser devida a um mecanismo de compensação em 
consequência da indução da subexpressão de uma subunidade do complexo I da CRM, 
GRIM-19. 
Em conclusão, como já fora publicado, confirma-se que a subexpressão de GRIM-19 
em CCCR não é justificada por mutações ou alterações a nível transcripcional. Por outro 
lado, o estado de metilação da hipotética região do promotor do gene GRIM-19 por si só 
também não explica porque é que a linha celular Caki-2 tem uma expressão maior do que a 
linha celular 786-O. Contudo, os resultados deste trabalho levantam pela primeira vez a 
hipótese de que a região do promotor do gene GRIM-19 estará hipermetilada e que poderá 
existir um mecanismo de repressão por factores de transcrição a regular a transcrição do 
GRIM-19 em CCCR. Por último, a interacção do GRIM-19 em particular com o p-
STAT3Ser727 pode ter um papel determinante na tumorigénese de CCCR mas ainda são 
necessárias mais investigações para confirmar esta hipótese. 
Os resultados deste trabalho sugerem que proteína /gene GRIM-19 terá um papel 
mais abrangente na tumorigénese de CCCR e também revelaram várias evidências de que 
este assunto merece um desenvolvimento mais aprofundado devido a uma potencial 
contribuição para terapias antineoplásicas. 
 
 
 
 
 
 
 
Palavras-chave: Proteína mitocondrial; GRIM-19; STAT3; Tumorigénese; Carcinoma de células 
claras renais.
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1.1 Cancer - classical and additional hallmarks 
 Luo et al. [1] states that “Cancer is a complex collection of distinct genetic diseases 
united by common hallmarks”.  
Currently, there is no doubt that cancer arises through a multistep process. It is stated 
that cancer development is consistent with Darwinian principles meaning that, cancer 
evolves through random mutations and epigenetic changes that alter these pathways 
followed by the clonal selection of cells that can survive and proliferate under 
circumstances that would normally be deleterious [1]. 
In 2000, Hanahan and Weinberg published a review that outlined six classical cancer 
hallmarks: unlimited proliferation potential, self-sufficiency in growth signals, insensitivity 
to antigrowth signals, evading apoptosis, sustained angiogenesis (attract new blood vessels 
to supply with nutrients and oxygen) and tissue invasion and metastasis (to distal organs) 
[2]. However, due to the progress of the last decade, it has been now proposed six additional 
cancer hallmarks: DNA damage, replication stress, proteotoxic stress, mitotic stress, 
metabolic stress and oxidative stress. Despite, these are not responsible to initiating 
tumorigenesis, they are common features of different types of tumors and they are 
collectively referred as the stress phenotypes of cancers [1].  
Indeed, these both classic and additional hallmarks interplay in a functional point of 
view, promoting tumorigenesis and suppressing oncogenic stress, as elucidated in figure 1. 
For instance, tumor cells use preferentially glycolysis which provides them advantages such 
as adaptation to hypoxia (low oxygen environment) and the acidification of 
microenvironment allowing tumor invasion as well as suppressing immune surveillance [3].  
Tumors are also characterized to have chromosome instability phenotypes that can 
result from defects in different pathways involved in mitosis thus, inducing mitotic stress 
and consequently promoting aneuploidy (altered chromosome number) [1]. On the other 
hand, the mentioned stress phenotype can also influence the proteotoxic stress phenotype 
that is counteracted by the heat shock protein response pathway, the responsible for the 
proper folding and/or proteolytic degradation of proteins [1, 4]. Moreover, elevated levels 
of reactive oxygen species (ROS) promote DNA damage that normally cause senescence or 
apoptosis but that is overcomed by tumor cells [1]. 
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Figure 1. The Hallmarks of Cancer. Classical cancer hallmarks originally proposed by Hanahan and 
Weinberg [2] (top half, white symbols) and evasion of immune surveillance proposed by Kroemer and 
Pouyssegur [3]. Additional hallmarks that depict the stress phenotypes of cancer cells (lower half, colored 
symbols). Indications (black arrows) of the functional interplays among these hallmarks that promote the 
tumorigenic state and suppress oncogenic stress (adapted from [1]) 
 
1.1.1 Cancer cell energy metabolism 
The complex connection between metabolism and proliferation remains an exciting 
area of research. It is possible that additional metabolic pathways have not been described 
yet. Understanding this important aspect of biology is likely to have a major impact on our 
understanding of cell proliferation control and cancer. Furthermore, exploiting the 
metabolic dependencies of cancer cells will be an essential step forward for cancer 
treatment.  
It is well known that under aerobic conditions, non-proliferating (differentiated) cells 
process glucose, first to pyruvate via glycolysis in the cytosol and afterwards to carbon 
dioxide through oxidative phosphorylation in the mitochondria; under anaerobic conditions, 
glycolysis is the favored pathway to produce energy [5].  On the contrary, tumors cells have 
a characteristic glycolytic phenotype. As described by Otto Warburg, more than 50 years 
ago, tumor cells tend to convert most glucose to lactate, even in the presence of sufficient 
oxygen levels to support mitochondrial oxidative phosphorylation [6]. This phenomenon is 
designed aerobic glycolysis or Warburg effect (an equivalent of fermentation used by many 
unicellular organisms to proliferate). However, the efficiency of ATP production is higher 
by oxidative phosphorylation than by metabolism of glucose to lactate, generation of 36 
ATPs against 2 ATPs per molecule of glucose. This raises the question of why a less 
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efficient metabolism, at least in terms of ATP production, would be selected by 
proliferating cells. Two possible explanations are: inefficient ATP production is perhaps a 
problem only when resources are scarce or most likely, proliferating cells to replicate all of 
their cellular contents need glucose for other additional requirements rather than just for  
ATP production (as source of energy). Besides to support cell growth and division, cells 
also needs glucose for synthesis of macromolecular precursors such as acetyl CoA which is 
required for fatty acids and NADPH for synthesis of amino acids and nucleotides [5].  
The excessive generation of lactate observed in the Warburg effect would appear to 
be an inefficient use of cellular resources. In fact, for each lactate excreted, a cell wastes 
three carbons that may be used for either ATP production or macromolecular precursor 
biosynthesis. However, there are evidences that tumors have a heterogeneous cellular 
metabolism since some cells seem to use the excess lactate as a fuel for mitochondrial 
oxidative phosphorylation. Indeed, Sonveaux et al. [7] reported a “metabolic symbiosis” 
between hypoxic and aerobic cancer cells. Basically, it is assumed that lactate produced by 
hypoxic cells during glycolysis is taken up by aerobic cells (which are closer to the blood 
vessels) which then use it as their main substrate for oxidative phosphorylation. To explain 
this process, the authors evaluated the monocarboxylate transporter 1 (MTC1), located at 
the cell plasma membrane, as the principal responsible to sustain the symbiosis process. As 
illustrated in figure 2, with MTC1 inhibition, oxidative tumor cells switch from lactate 
oxidation to glycolysis avoiding adequate glucose delivery to hypoxic cells, which die from 
glucose starvation and become more susceptible for radiotherapy treatment [7].  
Undoubtedly, this metabolic reprogramming is orchestrated by hypoxia-inducible 
transcription factor1 (HIF-1) through the transcriptional activation of key genes encoding 
metabolic enzymes, such as:  GLUT1, which encodes a glucose transporter that increases 
glucose uptake during glycolysis [8]; hexokinase II,  which catalyze the irreversible  first 
step of glycolysis (glucose is phosphorylated to glucose-6-phosphate) [9]; LDHA, encoding 
lactate dehydrogenase A, which converts pyruvate to lactate [10] and PDK1, encoding 
pyruvate dehydrogenase kinase 1, which inactivates the enzyme responsible for conversion 
of pyruvate to acetyl-CoA, thereby shunting pyruvate away from the mitochondria [11,12].   
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Figure 2.  Lactate uptake and schematic representation of the suggested metabolic symbiosis in 
tumors (adapted from [7]). 
Moreover, HIF-1 is also responsible to induce a transcriptional program by 
stimulating angiogenesis through the induction of VEGF-A and angiopoietin-2 [13]. Hence, 
the role played by the increased activity in HIF-1 in cancer development will continue to be 
a target of investigation specially due to its connection with mitochondrial alterations. 
 
 
1.2 Targets for cancer therapy 
Nowadays, Science continues to have a big challenge which is: “The Path Ahead to 
New Cancer Therapeutics” [1]. 
Several efforts have been done to achieve progresses in this field. Of note, there are 
many approaches, like the Cancer Genome Atlas [14], that aim to characterize, in a large 
number of cancer types, genomic alterations including copy-number variation, 
transcriptional profiles, epigenetic modifications and DNA sequence alterations. Even if it 
is expensive, these are a kind of approaches very important to yield new information on 
human cancer, aid biomarker discovery and help to stratify patients. It can be done, for 
example, by identification of common alterations in oncogenes and tumor suppressors for 
further functional analysis and uncover oncogene addiction pathways that can be targeted 
[14, 15,16]. However, this kind of studies have limitations as they do not have in account 
non coding regions analysis as well as analysis of the non-oncogenes function. The latter 
 
 
 
 
11 
comes from a recent concept that cancer cells are addicted to both oncogenes and non-
oncogenes. This phenomenon was termed by Solimini et al. [17] as “non-oncogene 
addiction” (NOA). Indeed, NOA genes, like oncogenes, support tumorigenesis but they do 
not undergo oncogenic mutations or have significant functional genomic alterations in 
tumors. Thus, NOA genes and pathways provide important targets for antitumor therapies 
[1].  
Ideally, researchers expect to discover a “druggable genome” which represents 
proteins with enzymatic functions that can be easily assayed or targeted.  Important 
progresses have been done and now the RNA interference (RNAi) itself seems to be the 
cancer therapy of the near future [18]. But, regardless to the target proteins, there are 
evidences that targetting metabolic pathways ( part of tumor- intrinsic NOA) will give extra 
advances in cancer therapy as there are some potential candidates that are overexpressed in 
certain cancer types such as the proteins:  GLUT1, HKII, phosphoglycerate dehydrogenase 
(PHGDH) and LDH-A [19]. 
For instance, GLUT1 is overexpressed in many cancer types including renal cell 
carcinomas (RCCs) that exhibit loss of the von Hippel-Lindau (VHL) tumor suppressor 
gene [20,21]. Interestingly, a recent study identified a series of small molecules that inhibit 
GLUT1 and selectively kill VHL deficient RCCs [21]. Same was observed with the other 
enzymes in other tumors [19]. 
However, this apparent inhibition efficiency leads with an important issue/future 
challenge. The question remains whether inhibition the abovementioned proteins, also 
expressed in normal tissues, will be effective in diminishing tumors without imparting 
significant toxicity to normal tissues [19]. 
Overall, promising advances in nanomedicine seem to overcome these limitations 
regarding drug delivery directly to targeted cells and tissues. For example, carbon 
nanotubes may be a very efficient tool thus it is a good candidate as part of a new era of 
cancer therapy [22].  
 
 
1.3 Regulation of mitochondrial metabolism and role of a nuclear gene  
 
         Mitochondria are organelles responsible for energy production required for cellular 
metabolism (producing most of the cellular ATP (adenosine-5′-triphosphate) via the 
oxidative phosphorylation (OXPHOS)). However, they have also an essential role in cell 
death regulation [23, 24]. 
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          In fact, mitochondrion is a special organelle and semi-autonomous as it possess its 
own genome which encodes some machinery necessary for their replication, transcription, 
translation and protein assembly [24, 25]. Each mitochondrion has about two to ten 
molecules of its own DNA, the mitochondrial DNA (mtDNA). Its  16.5kb circular double-
stranded molecule encodes 22 transfer RNAs (tRNAs) and 12S and 16S ribosomal RNA 
(rRNA), as well as 13 proteins (highlighting in orange boxes, see Figure 4) which are part 
of the mitochondrial respiratory chain (MRC) and OXPHOS system (Figure 3) [23, 26]. 
Despite having their own DNA, mitochondria are not independent from the nuclear DNA 
(nDNA) because most mitochondrial proteins are encoded by nDNA which are imported 
into the mitochondria [24]. GRIM-19 is an example of a nuclear gene that encodes a 
mitochondrial protein. 
          The nDNA encodes approximately 80 OXPHOS proteins, required for the 
mitochondrial metabolic pathways as well as for all of the enzymes required for 
mitochondrial biogenesis including mtDNA polymerase γ (POLG), RNA polymerase, 
mtDNA transcription factors and ribosomal proteins, among others [27]. 
          As shown in Figure 3, the mitochondria respiratory chain (MRC) is composed by four 
complexes (complex I- IV) involved in the electron transport chain and complex V (ATP 
Synthase) which is responsible for ATP synthesis [28]. There, it can be possible to identify 
which genes/proteins are related with each complex. 
 
Figure 3. Schematic representation of oxidative phosphorilation system (OXPHOS) in the 
mitochondria. In the scheme are represented the genes/ proteins present in each complex. Orange boxes 
highlighting mtDNA encoded OXPHOS proteins and green boxes highlinting nDNA –encoded 
mitochondrial proteins such as GRIM-19 subunit (adapted from [23]). 
 
Several studies published to date show that mutations in mitochondrial proteins 
(regardless of codified by nuclear or mitochondrial genes) are commonly associated with 
hereditary and sporadic tumors. It is also known that tumor cells acquire distinctive 
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metabolic features which confers them some growth advantage (Warburg effect or aerobic 
glycolysis) [29, 30]. The Warburg effect (decrease of MRC activity and increase of 
glycolysis which means that cancer cells produce lactate even in the presence of oxygen) 
has been demonstrated in different type of tumors and in fact, it has been explored clinically 
for detection of tumors by Fluorodeoxyglucose positron emission tomography [23,29]. 
Although this metabolic shift is now being considered a hallmark of cancer cells, its origin 
remains to be established. Nonetheless, it is tempting to speculate that mutations in genes 
coding mitochondrial proteins force cells towards glycolysis thus leading to their particular 
metabolic profile. 
Interestingly, a nuclear gene coding a mitochondrial protein that has emerged to be a 
key player in growth and apoptosis was a gene associated with retinoid-IFN-induced 
mortality (GRIMs), particularly GRIM-19. This gene was identified by a research group 
interested in unveiling the molecular basis of cell death associated with exposure to 
interferon (IFN)-β and retinoic acid (RA) (a derivative of vitamin A) [31].IFNs and RA 
have both been shown to suppress tumor growth thus they are used in the treatment of 
several cancers [32-34]. 
In 2000, by employing an anti-sense knock-out approach, Angell et al. [34] were able 
to isolate genes associated with retinoid-IFN-mortality (GRIM),among which was GRIM-
19. The authors verified that the antisense GRIM-19 (reduce intracellular levels of GRIM-
19) was able to confer a strong growth advantage to cells when exposed to the combination 
of IFN-β and RA treatment [34]. 
Interestingly, overexpression of GRIM-19 was able to reduce cell viability (only 
resistant cells form colonies), while cells expressing moderate levels of GRIM-19 were 
significantly more susceptible to cytotoxic effect of IFN/RA. GRIM-19 seemed to induce 
apoptosis under IFN/RA combination [34]. 
At that time, GRIM-19 gene was characterized to have a 552 base pairs (bp) cDNA 
and to codify a protein with 16kDa [26]. On the other hand, and also in 2000, Chidambaram 
et al. [35] identified the chromosomal location of human GRIM-19- 19p13.1 – 13.2.  Once 
that human chromosome 19p13.2 locus was associated with genes that can suppress prostate 
and thyroid tumor cell growth [36, 37], then it was suggested that GRIM-19 could be one 
candidate as tumor suppressor gene [35]. 
In fact, like other tumor suppressor proteins such as p53, mutations in GRIM-19 gene 
and absence of its protein expression have been observed in different types of tumors [38-
45]. Notably, mutations in the GRIM-19 gene were identified in a particular histotype of 
thyroid tumors and this was the first nuclear gene associated with Hürthle (mitochondrion-
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rich) cell tumors to be reported [38]. More recently, it has been observed a very weak or 
complete lack of GRIM-19 protein expression in renal tumor cells but curiously no 
mutations were observed [39]. Furthermore, several studies shown that GRIM-19 
interaction with STAT3 protein are relevant in tumor progression [40-45] and recent 
findings describe that STAT3 also seems to regulate mitochondrial metabolic function. 
Therefore, further investigations must be done to disclose how those proteins may be 
involved in the mitochondria metabolic shift [46, 47]. 
 
1.4  GRIM-19: a subunit of complex I of mitochondria 
          One year after GRIM-19 identification, Fearnley et al., [48] reported an additional 
protein of the 42 MRC complex I subunits described in bovine heart mitochondria. In their 
study it was observed a new subunit (B16.6) of MRC complex I that corresponded to the 
bovine homolog of the GRIM-19 human protein (83% of identity). 
        Later, Huang et al. [49] using different tumoral cell lines (cervical, breast, kidney and 
neuronal pheochromocytoma cells) to re-examine whether the localization of GRIM-19 is 
exclusively on mitochondria, showed that GRIM-19 protein is exclusively located on the 
cytoplasm with no immunofluorescence staining of GRIM-19 in the nucleus. Furthermore, 
the authors investigated the localization of GRIM-19 at a sub mitochondrial level using 
antibodies for complexes subunits of MRC [49]. As shown in Figure 4, absence of GRIM-
19 (GRIM -/-) induced a drastic decrease of complex I expression while complex II 
expression was not affected. Interestingly, at complex III level occurred also a certain 
decrease of expression. These results demonstrate that in fact, GRIM-19 is an essential 
component of MRC as it not only ensures complex I assembly but it could also influence 
assembly of other complexes thus interfering with the electron transport chain, leading with 
mitochondrial failure [49]. 
 
Figure 4. Effect of GRIM-19 in the expression of other complexes subunits.  Western blot analysis 
using cell lysates from wild-type and GRIM-19 -/- blastocytes (adapted from [49]). 
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        Some studies of knockout studies, in blastocytes of mice [49], and knockdown, in 
Xenopus embryos [50], of GRIM-19 gene, demonstrate that this gene is essential for 
assembly and activity of complex I. However, while these results did not elucidate how it 
occurs, Lu & Cao [51] addressed this question and decided to study the functional domains 
of GRIM-19 protein. From this study, it was concluded that N-terminal domain ( aa 1-60) is 
essential for mitochondrial localization of GRIM-19 and also for its incorporation to 
complex I; the middle region (aa 70-100) is required for electron transfer activity of 
complex I and the last C-terminal (10 aa) promotes GRIM-19 assembly to complex I of 
MRC [51].  
In addition, it was also demonstrated that GRIM-19 is essential for early embryonic 
development in mice, as genetic ablation of this gene by homologous deletion leads to 
embryonic lethality by day 9.5, particularly due to oxidative phosphorylation (OXPHOS) 
failure [49]. 
          All these evidences show that GRIM-19 gene has a double role as it is involved in 
cellular death induced by IFN-β /RA as well as in the mitochondria metabolism. 
Nonetheless, it was recently published that GRIM-19 is present in the nucleus, 
mitochondria or cytoplasm [52, 53]. Indeed, it not completely clarified this question related 
with GRIM-19 localization. However, as referred by Máximo et al. [54], this variable 
localization could reflect the different functions of GRIM-19 in cellular biology, as part of 
MRC, of apoptosis pathway induced by IFN-β /RA and also its interaction with cytosolic 
proteins such as STAT3 protein. 
 
 
1.5  GRIM-19 and other proteins interaction 
There are several studies confirming some partners of GRIM-19 involved in growth 
suppression such as GW112 [55], HtrA2 [56], NOD2 [57], p16Ink4a [58] and in particular 
STAT3 protein [40,41,59].In fact, the interaction of GRIM-19 with the latter protein has 
been investigated in several studies in order to understand how these proteins interact. It 
was observed, in different types of human tumors, an overexpression of STAT3 protein and 
by inducing overexpression of GRIM-19 it seems to inhibit STAT3 protein activity in a 
translational level and also increase apoptosis of tumor cells. 
1.5.1 STAT3 and its interaction with GRIM-19 
        STATs (Signal Transducers and Activators of Transcription) are key mediators of 
cytokine signaling and whose activation occurs through Janus Kinase (JAK) pathway. 
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Subsequently, STAT proteins are translocated to the nucleus where they exert their DNA-
binding activity and thus, inducing transcription of genes involved cell proliferation, 
differentiation, cell survival and development [60]. 
STAT3 is one STAT family member that is involved in embryonic development [61], 
cell growth and anti-apoptosis [62]. Usually, STAT3 is tightly regulated by feedback 
inhibitors. However its constitutive activation has been documented and directly contributes 
to oncogenesis in cells transformed by viruses, oncogenes and autocrine growth factors [41, 
60] and it was observed in tumors [60, 63, 64]. STAT3 is responsible for the expression of 
some genes involved in cell proliferation like cyclins B1 and D1, cdc2, c-myc, and 
antiapoptotic proteins like Bcl-XL, Bcl-2 and Mcl-1, p21WAF1/CIP1 [60]. 
In general, STATs (and in particular STAT3) are predominantly in a latent state in the 
cytoplasm. When a ligand binds to the extracellular domain of the cytokine receptors and 
activates them, the intracellular receptor associated JAK is activated by 
autophosphorylation. This leads to phosphorylation of tyrosine residue (Tyr705) in 
monomeric and unphosphorylated STAT3, which becomes active and ready to dimerize by 
the SH2 (Src-homology 2) domains from each one. The dimerization is essential for STAT3 
because allows its translocation to the nucleus where it exerts its biological function through 
DNA binding [60, 65, 66]. However, there are evidences that another phosphorylation, on 
the serine residue (Ser727) is important to STAT3 activation, but its relevance is not 
completely clear.  
Some studies pointed that phosphorylation at the serine residue (Ser727) is 
fundamental to the optimal transcriptional activation of STAT3 after the tyrosine residue 
(Tyr705) phosphorylation [67, 68]. Other studies showed that Ser727 phosphorylation can 
be essential for STAT3 signalling, once its blockage can eliminate this signalling 
[60,69,70]. Moreover, there are studies indicating that Ser727 phosphorylation may result in 
STAT3 signalling activation independently of Tyr705 phosphorylation under certain 
conditions [71-73]. More recently, Wegrzyn et al. described that STAT is present in 
mitochondria and the Ser727 phosphorylation was reported to be important to this 
localization, independently of the function in the nucleus [47]. 
 In summary, STAT3 activation and function lead to a lot of questions and it is 
necessary further investigation to clearly understand this issue.  
In 2003, the first evidences that STAT3 and GRIM-19 are interacting proteins were 
shown. First, Lufei et al. [40], using a yeast two hybrid assays (Y2H), identified GRIM-19 
as specific STAT3 interacting protein (do not interact with STAT1 or STAT5) and this 
interaction was demonstrated both in vivo and in vitro [40]. Afterwards, Zhang et al. [41] 
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using the same technique to identify other GRIM-19 protein partners, confirmed GRIM-
19/STAT3 interaction. Indeed, both studies confirmed that GRIM-19 interacts specifically 
with STAT3, but not with other STATs (1, 2 and 5a STAT) family members [40, 41]. 
Zhang et al. [41] also observed that after IFN/RA treatment (inducers of GRIM-19 
expression), more STAT3 was co-immunoprecipitated with GRIM-19 in comparison with 
unstimulated cells, which was supposed to be caused by an increase of GRIM-19 expression 
[41]. 
These two studies presented some contradictory aspects related to the primary 
domains of STAT3/GRIM-19 binding and to the mechanism by which GRIM-19 blocks 
STAT3 activity. Nevertheless, both studies identified STAT3 as an intervenient of the 
GRIM-19 death-inducing pathway and GRIM-19 as a novel inhibitor of STAT3 [40, 41]. 
Due to this ambiguous issue related with GRIM-19 role in oncogenic cell 
proliferation and its effects in a constitutively active STAT3, Kalakonda et al. [59] 
developed a study using a human prostatic cell line (PC3 cells). The authors observed that 
by inducing STAT3 activation (enhance oncogenic features) and when GRIM-19 vector 
was introduced and cells expressed it, colony formation by these cells decreased. This 
capacity of GRIM-19 protein to inhibit STAT3 function, particularly, the expression of 
endogenous genes involved in cell growth control was also observed in vivo as GRIM-19 
was able to inhibit tumor formation [59]. 
Nonetheless, in 2010, Nallar et al. [53] identified one of the structural elements 
responsible for GRIM-19 antitumoral function. The authors identified a motif of four amino 
acids: glutamic acid, aspartate, methionine and proline – QDMP- in N-terminus of GRIM-
19, considering it as the main responsible for STAT3 repression.  The authors observed that 
by promoting a deletion in this motif the capacity of this mutated GRIM-19 to suppress 
growth was lower than the wild-type GRIM-19. Therefore, so far, N-terminus is the major 
responsible for GRIM-19 function in cell growth (inhibition of genes involved in cellular 
cycle regulation) [53] and motility/invasion (inhibition of proto oncogenes such as src) [74]. 
Interestingly, a tumor-derived mutation described by our group [38], located at N-terminus 
(lysine converted to an asparagine in amino acid 5 – K5N) was also unable of inhibit colony 
formation in soft-agar and limit cell growth [53]. 
 Still back in 2009, it was shown that STAT3 is present in mitochondria and has a 
regulatory function in OXPHOS, particularly in MRC complexes I and II [47]. Based in 
previous studies reporting GRIM-19 interaction with STAT3 [40, 41] and GRIM-19 effects 
on MRC [48, 49], the authors supposed that STAT3 might also co-localize with GRIM-19 
in mitochondria. Thus, using an SDS-PAGE, the hypothesis was confirmed, although the 
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co-localization observed was relatively smaller in mitochondria comparing to the cytosol 
fraction. Using STAT3 knockout cells (STAT3-/-) it was shown that STAT3 is essential for 
complexes I and II activity, since their activity was significantly decreased in these cells and 
STAT3a (a STAT3 isoform) restoration were able to restore the activity of these complexes 
[47]. 
Recently, a study demonstrated more evidences that mitochondrial STAT3 (p727 
STAT3) is necessary for the maximal activity of complex I and II activity in the MRC [75]. 
Moreover, it was suggested that this regulation is direct and independent of STAT3 
transcriptional activity (Figure 5). Basically, overexpression of mitochondrial –targeted 
STAT3 blocks partially the electron flow within complexes I and II that does not impair 
mitochondrial membrane potential nor enhance the production of reactive oxygen species 
(ROS). Consequently, less ROS and lack of cytochrome c translocation from mitochondria 
inner membrane into the cytosol attenuates apoptosis. Thus, it is possible to enhance cell 
viability even under stress conditions (such as, absence of oxygen) [75]. 
 
 
 Figure 5. A novel protective mechanism mediated by mitochondrial STAT3 that is independent of 
its canonical activity as a nuclear transcription factor During stress conditions, such as cardiac 
ischemia, STAT3 works both as a signaling molecule involved in regulation of cardioprotective gene 
expression and as a direct modulator of complex I of the mitochondrial electron transport chain. Y705, 
tyrosine 705; C-I, -II, -III and -IV, respiratory complex I, II, III, and IV (adapted from [76]). 
 
 
Indeed, it is necessary to investigate which is the mechanism by which STAT3 
regulates complex I and II of the MRC. This will be a crucial aspect to clarify what is the 
role of STAT3 in the cellular metabolism once that it seems to be a function apart from the 
role as transcription factor in the regulation of nuclear genes expression. 
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1.6   GRIM-19 and tumorigenesis 
Several studies reported absence or reduction of GRIM-19 protein expression in 
different types of tumors [38,39 ,42 ,43,52]. 
          In thyroid tumors, there is a consensual relation between downregulation of GRIM-19 
protein and oncocytic tumors, the Hürthle cell tumors as described by Máximo et al. [38]. 
Furthermore, Gong et al. [42] analyzed in human colorectal tissues the expression of 
GRIM-19 and STAT3 and they observed that GRIM-19 expression was lower in tumor 
samples compared to normal colorectal tissues. At same time, it was concluded that STAT3 
expression is negatively correlated with GRIM-19 expression [42], which is an inhibitor of 
STAT3 protein [40,41]. Same results were observed by Zhang et al.  [43] in primary human 
prostate carcinomas by performing an immunohistochemical assay. Moreover, the same 
authors investigated the opposite effects of STAT3 and GRIM-19 in cell growth in vitro and 
in vivo. The authors constructed a STAT3-specific short hairpin RNA (shRNA – a RNA 
interference molecule) in order to reduced STAT3 expression in prostate cancer PC-3M 
cells. In parallel, they enhanced GRIM-19 expression and observed an inhibition of the 
STAT3-dependent genes and a suppression of cell growth in a synergistic way. The same 
conjugation, shSTAT3 and GRIM-19 overexpression, were tested in vivo from which was 
possible to observe tumors with smaller size than the controls and by TUNEL assay, these 
smaller tumors presented a higher number of apoptotic cells [43]. 
        Another study in human cervical cancer, the most common gynecologic neoplasm in 
women, confirmed once more GRIM-19 involvement in cancer [44].  Zhou (Y) et al. [44] 
demonstrated the existence of a correlation between GRIM-19 downregulation and high 
basal levels of STAT3 and STAT3 target genes (cyclin B1, Bcl-2-L1). On the other hand, it 
was demonstrated that the restoration of GRIM-19 levels in HeLa cells induces an efficient 
tumoral suppression due to inhibition of invasive factors (MMP-2 and MMP-9) and 
angiogenic factors (VEGF) [44]. More recently, similar results were observed in a study 
involving human glioma cells [45]. GRIM-19 expression negatively regulated the 
phosphorylation of STAT3 and prevented translocation of STAT3 from the cytoplasm to 
the nucleus in malignant glioma cells. This study shown not only that GRIM-19 expression 
regulates the activation of STAT3 and the expression of many STAT3-dependent genes but 
it also suggests that GRIM-19 induces glioma cell apoptosis through a STAT3-independent 
mechanism[44]. Interestingly, in contrast to the mentioned cervical cancer study [44], 
GRIM-19 seems to suppress glioma cell migration probably through inhibition of MMP-9, 
but not MMP-2[45].   
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In lung tumors was also reported by   Zhou (A) et al. [52] that in non-small cell lung 
cancer (NSCLC), GRIM-19 was significantly lower (24.3%) than in normal lung tissues 
[52]. These authors observed that GRIM-19 expression correlates with clinicopathological 
factors of lung cancer (positive rate of GRIM-19 in clinical stages I and II was higher than 
in stages III and IV or NSCLC). It was also observed that in normal lung tissues GRIM-19 
is primarily located in the cytoplasm, but in lung cancer tissues it is predominantly located 
in the nucleus [52]. It corroborates with the idea that GRIM-19 translocates from the 
cytoplasm to the nucleus in order to inhibit STAT3 protein function related with 
tumorigenesis [40, 41]. 
In summary, all the mentioned facts reinforce the idea that GRIM-19 is an essential 
protein in the progress of tumorigenesis. Thus, GRIM-19 is a double-edged sword [39] - 
first as a mitochondrial protein, responsible to ensure energy production at the cellular level. 
On the other hand, it is also a protein with suppressor activity as it inhibits expression of the 
transcription factor STAT3. Therefore, absence of GRIM-19 promotes an excessive cell 
growth due to deregulation of the two aforesaid pathways, giving an advantage to tumors 
cells. 
 
 
1.7    GRIM-19 and kidney cancer 
Over the last three decades, kidney cancer incidence has been rising in Europe and 
the United States each year. In fact, kidney cancer is diagnosed in approximately 271000 
people worldwide and 116000 persons have died from the disease [77].Thereby, it accounts 
for 2% of the adult malignancies being more frequent in men.  
Of note, renal cell carcinoma (RCC) comprise 80-85% of the kidney cancer [77] and 
its  higher incidence (Western and Eastern Europe countries, Scandinavia, Italy, North 
America, Australia and New Zealand) might be associated with the most associated risk 
factors of kidney cancer such as obesity, smoking and hypertension [78].  
From the five major histological subtypes of RCC, including type 1 papillary RCC, 
type 2 papillary RCC, chromophobe RCC, oncocytomas, clear cell renal cell carcinoma 
(ccRCC) is the most common histological subtype[79]. Typically, this subtype of RCC is 
characterized by the presence of cells with a clear cytoplasm that are arranged in sheets, 
acini or alveoli with a prominent thin-walled vasculature (Figure 6A) [79, 80].Since its 
isolation in 1993 by Latif, clear cell RCC became the most well studied type of inherited 
renal cell carcinoma whose main cause is a von Hippel Lindau (VHL) mutation [81]. VHL 
gene regulate activation of hypoxia pathway so, inactivation of VHL gene promotes 
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expression of transcription factor which induces expression of Hypoxia associated-genes 
(HIF), such as VEGF (vascular endothelial growth factor) which is responsible to enhance 
angiogenesis process. This explains the characteristic high vascularity of the histological 
subtype ccRCC [82]. However, HIF-1α has many other targets which are associated with 
human tumorigenesis, such as genes involved in survival, motility, extra-cellular matrix 
modification and glucose metabolism [83].  
Under hypoxia conditions, VHL loss of function leads, in aerobic conditions, to HIF-
1α-dependent metabolic shift from oxidative to glycolytic metabolism, through increased 
glucose uptake and lactate production associated with a reciprocal decrease in 
mitochondrial respiration (Warburg effect) [84].  Additionally, in RCC it has been reported 
a reduced levels of mitochondrial DNA and respiratory chain proteins as well as increased 
levels of glycolytic enzymes [85-87]. GLUT1 protein expression has been demonstrated at 
the earliest stages of tumor formation [88] and high lactate dehydrogenase A (LDHA) and 
low mitochondrial respiratory chain content are both associated with poor prognosis in 
advanced RCC [89,90]. Those aspects show evidences of a link between VHL /HIF- α, 
mitochondrial dysfunction and tumorigenesis but it still needs further investigation to be 
consider a robust interrelation. 
 
 
 
 
 
 
 
Figure 6.  Two of the five histological subtypes of renal cell carcinoma. A) Clear cell renal cell 
carcinoma (ccRCC) showing cells with a clear cytoplasm which is histologically very distinct from, for 
example B) oncocytoma, benign tumor, in which cells have an eosinophilic cytoplasm due to a high 
number of mitochondria (adapted from [79]). 
 
Recently, a review of Arai et al., on renal tumorigenesis, reported that it is necessary 
to develop more studies to identify other key molecules to use in kidney cancer prevention, 
diagnosis and therapy [91]. Interestingly, in 2006, Alchanati et al. [39] demonstrate that 
GRIM-19 may act as a central molecule in RCC, regardless of the histotype of the tumors. 
By proteomic analysis, the authors observed differences between the proteins present in 
A B 
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samples from clear cell RCC and normal renal tissues. Then, they focused their study on 
one particular spot which was observed constantly in the normal tissues but absent in tumor. 
They conclude that the spot analyzed corresponded to GRIM-19 protein. By Western blot, 
using a specific antibody for the GRIM-19 protein, they confirmed a complete lack or 
reduction of GRIM-19 expression in eleven of the clear cell RCC samples in contrast to its 
abundant expression in the paired normal samples [39]. However, in opposite to thyroid 
tumors [38], no mutations were identified in renal cell carcinomas except in one out of six 
cases of clear cell RCC analyzed [39]. These results indicate that GRIM-19 downregulation 
probably occurs through inhibition of transcription rather than by genetic mutations. 
 Nevertheless, there are studies showing that STAT3 is involved in the activation of 
the HIF-1. Like VHL gene inactivation, the loss of GRIM-19 expression may also 
contribute to deregulation of HIF-1 expression, in this case, through interaction with 
STAT3 thus, promoting tumoral angiogenesis [92].  
            The study by Alchanati et al. [39] also gives rise to the hypothesis that, at least, in 
RCC, alterations related with GRIM-19 protein are not related with excessive number of 
mitochondria in tumor cells. However, this protein seems to be crucial in the renal 
tumorigenesis as recently observed by immunohistochemistry assay performed by our 
group (unpublished data). Moreover, Alchanati et al. also stated that clear cell RCC is the 
histological sub-type that presents the highest downregulation of GRIM-19 [39]. 
Furthermore, there are already some evidences that STAT3 plays also an important role in 
the tumorigenesis and proliferation of renal tumors however STAT3 activation in the 
different histotypes of renal tumors still needs to be clarified [93].   
          Notably, the list of tumor-related genes silenced by DNA hypermethylation during 
renal carcinogenesis has been increasing [91]. As an example, almost twenty years ago, 
Herman et al. have demonstrated DNA hypermethylation of the VHL gene in 19% of 
examined RCC tumors [94]. Treating a renal cancer cell line with 5-aza-2’-deoxycytidine 
resulted in re-expression of the VHL gene. Thus, the VHL gene became, after RB gene, the 
second known tumor-suppressor gene silenced by DNA methylation [90]. Indeed, more 
studies have been focusing this issue and last year, Morris et al. published a study when 
they identified epigenetically inactivated candidate tumor suppressor genes in renal cell 
carcinoma [95]. The authors used a genome-wide strategy combining two techniques 
(methylated DNA immunoprecipitation (MeDIP) and whole-genome array analysis in 
combination with high-density expression array analysis) to identify genes that are 
frequently methylated and silenced in RCC [95]. A recent review by Henrique et al. 
summarizes the current knowledge about epigenetic mechanisms in renal cell tumors 
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(RCTs). The authors referred a list of commonly methylated gene promoters in RCTs, 
whose genes are involved in diverse pathways such as hormonal response, signal 
transduction, tumor invasion, angiogenesis and apoptosis [96]. 
         Indeed, the detection of promoter region hypermethylation and transcriptional 
silencing has facilitated the identification of candidate renal cell carcinoma (RCC) tumor 
suppressor genes [95]. As GRIM-19 is stated to be a potential tumor suppressor gene [35] 
and the mechanism responsible for GRIM-19 protein downregulation in RCC needs further 
investigation, it is tempting to speculate whether GRIM-19 expression and function is not 
also affected by some epigenetic inactivation. 
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         It is crucial to understand the etiopathogenesis of the tumors, since it will help to 
achieve better diagnosis, prognosis and possibly contribute for new therapeutic 
development. Hence this work has one main interest which is to improve the knowledge 
about kidney cancer etiopathogenesis, where the role of GRIM-19 as tumor supressor gene 
may be essential. The principal question is: why is GRIM-19 downregulation observed in 
all subtypes of renal cell carcinoma (RCC), particularly in clear cell renal cell carcinoma 
(ccRCC) whereas in thyroid tumors, downregulation of GRIM-19 is mainly observed in 
oncocytic tumors (Hürthle cell tumors, mitochondrion-rich).  
Therefore, with this study we propose to answer the following questions:  
 
a) what is the role of GRIM-19 in renal tumorigenesis;  
 
b) how does GRIM-19 protein expression interfere with the expression, activation and 
localization of STAT3 protein, particularly in the context of renal tumorigenesis;  
 
c) which is the mechanism behind GRIM-19 downregulation in renal cell carcinomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. MATERIAL and METHODS 
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3.1 Cell lines and cell culture conditions 
Caki-2 (ATCC number: HTB-47 TM) is a tumorigenic cell line isolated from a 
primary renal carcinoma by J. Fogh. 786-O (ATTC number: CRL-1932TM) is a tumorigenic 
cell line which was derived from a primary clear cell adenocarcinoma by RD Williams. 
HEK 293 (ATCC number: CRL-1573 TM) is an immortalized cell line derived from 
embryonic kidney tissue by FL Graham. 
All mentioned cells lines are epithelial and adherent cell lines (see more details in 
www.ATCC.com). 
Caki-2 cell line was maintained in McCoy’s 5a medium; 786-O cell line as well the 
cell lines derived from it shControl (shCT) and shGRIM-19 were maintained in RPMI 
1640; HEK 293 cells and their derived shCT and shGRIM-19 were maintained in DMEM. 
All media were supplemented with 10% (v/v) inactivated and filtered fetal bovine serum 
(FBS), 1% (v/v) penicillin/streptomycin (PenStrep) and 0.5% (v/v) fungizone. All cells 
were routinely maintained at 37°C, 5% CO2 in a humidified incubator and cultured as a 
monolayer. 
Regarding transfections, stable clones (shCT and shGRIM-19) were generated by 
selection with puromicin (2μg/mL) which was added to the respective medium of each 
parental cell line. 
All media and FBS were purchased from PAA as part GE Healthcare (UK); Trypsin-
EDTA, PenStrep and fungizone were purchased from GIBCO, as part of Invitrogen Life 
Technologies (Carlsbad, California, USA). 
 
 
3.2 Nucleic acids extraction from cell lines 
 
        3.2.1 DNA extraction  
This procedure was performed using Invisorb® Spin Tissue Mini Kit. The process 
was done accordingly to the manufacturer’s instructions (Invisorb® Spin Tissue Mini Kit, 
Invitek, Berlin, Germany) for DNA isolation from 10-106 eukaryotic cells/cell pellets.  
Extracted DNA was quantified using NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Delaware, USA) and DNase/RNase-free distilled water 
(Gibco,Invitrogen, Carlsbad, CA, USA) as blank. 
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        3.2.2   RNA extraction  
 
One mL of TRIzol Reagent (Life Technologies TM, California,USA) was added 
directly to the cells previously collected to an eppendorf of 2mL and the cell lysate ws 
passed several times through a pipette. The remaining protocol was performed according to 
manufacturer’s instructions (TRIzol® Reagent, Life TechnologiesTM, California,USA).  
RNA concentration was determined using NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Delaware, USA) using DNase/RNase-free distilled water 
(Gibco, Invitrogen, Carlsbad, CA, USA) as blank. 
 
3.3 Molecular Analysis of GRIM-19 Gene 
 
To analyze GRIM-19 gene, it was necessary to amplify each of its five exons (see 
Annex I) by Polymerase Chain Reaction (PCR), a technique developed by Kary Mullis in 
1986 [97]. 
PCR is an extremely sensitive and specific reaction involving the exponential 
amplification of DNA molecules for further downstream techniques to identify mutations 
such as automated sequencing. 
 
3.3.1 Polymerase Chain Reaction (PCR)  
 
The primer sequences (forward and reverse) were designed based in GRIM-19 
(NDUFA13) sequence available on ENSEMBL human sequence database. In table I are 
described the primer sequences, the size of the amplicon and the optimal annealing 
temperature obtained after PCR optimization.  
All PCR reactions were performed using ~100ng of genomic DNA extracted from 
cell lines, 0.1μM of each forward and reverse primers (Invitrogen, UK), 1x PCR Buffer (5x 
Green GoTaq® Flexi Buffer, Promega, WI, USA), 1.5mM of Magnesium Chloride Solution 
(Promega, WI, USA), 40mM dNTPs mix (Bioron GmbH, Germany) and 0.5U of GoTaq® 
DNA polymerase (Promega, WI, USA) and DNase/RNase distilled water 
(Gibco,Invitrogen, Carlsbad, CA, USA) to fulfill the total reaction volume of 25 µL. The 
PCR reactions were performed in BIO RAD MyCyclerTM thermal cycler (BIO RAD, CA, 
USA) with the following cycling conditions: a single pre-denaturation step at 95ºC for 5 
minutes, followed by 35 cycles of denaturation at 95ºC for 30 seconds, annealing at a 
variable temperature for 30 seconds, elongation at 72ºC for 30 seconds, and a final 
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elongation at 72ºC for 7 minutes. A negative control was included in each PCR reaction, in 
order to detect possible PCR contamination.  
Table I - Primers sequences and their correspondent temperatures. 
Exons Primers Sequence (5’-3’) 
Amplicons 
size (bp) 
Annealing 
Temperature(ºC) 
 
Exon 1 1F1- GCA ACA CCC CAG AGG CAA GGT GA ~352 57 1R- AGA CTC TGA GAC CCC GGC GCA 
Exon 2 2F- CAG TGT CCC CTG ATT GCA GAG 205 57 2R- ACT TTC AGA CAA CGC CCA CCA 
Exon 3 3F- GGT CTT GAC CTG AGT GTG GGT T 150 55 3R- CTT CCG GCC AGT GAC CTC CCA 
Exon 4 4F- AAA GGA GAC AGG GTC GGA GGG A 222 64 4R- TCT GCC GTG GCT GGC ACC TCT 
Exon 5 5F- GGT GGC TGT GCC TCT ACC CAT 261 55 5R- TTT CCC CCA GTC CCC AGG AAA 
F- forward primer; R- reverse primer 
 
3.3.2 Electrophoresis in agarose gel 
PCR products were separated by electrophoresis on a 2% w/v agarose gel and stained 
with Gel Star (Cambrex, Iowa, USA) ( a safer alternative of ethidium bromide which is 
carcinogenic) for staining nucleic acids and visualize them under UV light). Once 
polymerized, the gel was placed on an electrophoresis apparatus, previously filled with 
running buffer – 1x SGTB (prepared from stock solution 10x) (Grisp, Porto, Portugal). The 
addition of 5x Green GoTaq® Flexi Buffer in the PCR mix allowed reactions to be loaded 
directly onto gels without loading dye, as this buffer contains a blue and yellow dye which 
migrates at the same rate as a 3-5kb DNA and faster than primers (<50bp), respectively. 
One kb Plus DNA Ladder (Invitrogen, UK), was used to have a control for the fragment 
length that is being analyzed.  
The fluorescent intensity of the separated PCR products was visualized and 
photographed in the Quantity One – version 4.6.9 in the ChemiDocTM XRS Imaging system 
(BIO RAD, CA, USA). 
 
3.3.3 DNA extraction from agarose gel  
 
The EasySpin – DNA Gel extraction kit (EasySpin, Citomed, Lisboa, Portugal) was 
used to perform the DNA extraction. The procedure was performed as manufacturer’s 
instructions (EasySpin, Citomed, Lisboa, Portugal).  
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 Extracted DNA was quantified using NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Delaware, USA) and DNase/RNase-free distilled water 
(Gibco, Invitrogen, Carlsbad, CA, USA) as blank. 
 
 
3.4 Automated Sequencing Analysis 
 
First of all, PCR products were subjected to a purifying treatment using 1U/μL 
Exonuclease I and 0.05U/μL shrimp alkaline phosphatase (both from Fermentas Lisbon, 
Portugal) at 37ºC for 20 minutes, followed by heat inactivation for 15 minutes at 80ºC.  
 
Therefore, for sequencing reaction of the PCR products, a mix of 0.5 μL of BigDye® 
Terminator (Perkin-Elmer, California, USA), 2 μL of sequencing buffer (Perkin-Elmer, 
California, USA), 0.3 μL of the  reverse or the forward primer (0.1μg/μL) (Invitrogen, UK), 
3 μL of purified PCR product and DNase/RNase-free distilled water (Gibco, Invitrogen, 
Carlsbad, CA, USA) were added to a final volume of 10 μL were placed in a PCR reaction 
tube. The sequencing reaction was performed in a BIO RAD MyCyclerTM thermal cycler 
(BIO RAD, CA, USA) for the forward and reverse primers with the following cycling 
conditions: a single predenaturation step at 94ºC for 10 seconds, followed by 35 cycles of 
denaturation at 94ºC for 10 seconds, annealing at variable temperature for 10 seconds and 
elongation at 60ºC for 2 minutes, and a final elongation at 60ºC for 10 minutes. 
 
In order to submit each sample to the ABI prism 3130xl Automatic sequencer 
(Perkin-Elmer, Foster City, California, USA) the sequenced product had to be purified and 
precipitated.  Thus, a column of Sephadex (SephadexTM G-50 Fine, GE Healthcare Bio-
sciences AB, Uppsala, Sweden) was prepared adding 750μL of Sephadex (6.66g/100mL) 
and centrifuging at 3200 rpm, 4ºC for 4 minutes. The columns were transferred from the 
collecting tubes to a clean eppendorf, and the 10μL of sequencing reaction was added to the 
center of the columns. A centrifugation was performed at 3200 rpm, 4ºC for 4 minutes. The 
final product was dried and DNA was ressuspended in 15μL of formamide (Applied 
Biosystems, Norwalk, USA) to maintain the single stranded DNA.  
All the samples were then submitted to the ABI prism 3130 xl Automatic sequencer 
(Perkin-Elmer, Foster City, California, USA), for further automated sequencing analysis. 
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3.5 Isolation of tumor cell lines with stable knockdown of GRIM-19 
 
To evaluate the influence of GRIM-19 on tumor cell metabolism and in the 
expression of STAT3 protein, clear cell renal cell carcinoma cell lines (Caki-2 and 786-O) 
were transfected with shRNA constructs. HEK 293 cell line was already transfected in the 
same conditions as that described below. 
  3.5.1 Short hairpin RNA expression plasmids  
Short hairpin RNA (shRNA) constructs against NDUFA13 (GRIM-19) gene were 
obtained from OriGene Technologies (Rockville, Maryland, USA), including four 
sequences against different parts of the GRIM-19 gene (expression plasmids with gene-
specific shRNA cassetes) (table II), as well as two negative control plasmids, one without 
shRNA cassette insert (TR20003) and other containing non-effective 29-mer shGFP 
cassettes (TR30003) as a specific negative control for gene down regulation. 
The vector had also a puromycin-N-acetyl transferase gene located downstream of the 
promoter, resulting in resistance to this antibiotic. 
 
Table II - Sequences from the constructs. 
Designation Sequences 
TI311989 GTTGCCACTGTTACAGGCAGAAACCGACC 
TI311990 ACTGGAGCATAATGAAGTGGAACCGTGAG 
TI311991 ATCATGGCGGTGGCAGTAAGTCACTTCCG 
TI311992 ACTGCGAGTATGGCGGCGTCAAAGGTGAA 
 
         3.5.2   Reverse Transfection 
 
The ability of RNA interference molecules (such as shRNA) to silence gene 
expression has been proved to be valuable for studying gene function in cultured 
mammalian cells. However, high efficiency transfection of shRNA is not trivial. There are 
evidences that an alternative transfection procedure, termed reverse transfection offers 
several key benefits over the traditional pre-plating method once it bypasses several steps of 
the traditional procedure. 
In fact, reverse transfection is believed to increase cell exposure to transfection 
complexes often leading to greater transfection efficiency (see more details in 
http://www.invitrogen.com). Thereby, we opted to use this alternative method to proceed 
with GRIM-19 gene knockdown. 
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Basically, in preparation for transfection cells were tripsinized, collected, and counted 
using Z Series Particle Count and Size Analyzer (Beckman Coulter). In total 5.0x104 cells 
of Caki-2/ 786-O cell line were plated in a 6-well culture plate.  Reverse transfection was 
carried out using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA, USA) reagent and Opti-
MEM® Reduced Serum Medium (without phenol red) (Invitrogen, Carlsbad, CA, USA). 
The introduction of GRIM-19 shRNA into cells via transfection and posterior 
creation of stable cell lines were performed according to the manufacturer’s protocol 
(OriGene Technologies, Rockville, Maryland, USA). 
The selection using puromycin was started 24hours after transfection. 
Of note, the ideal concentration of puromycin (2μg/mL) was decided according to the 
concentration already described in the literature for these specific cell lines [98]. 
 
3.6 Western blot analysis 
Cell lines were washed twice with PBS and subsequently lysed using RIPA buffer 
(1% NP-40 in 150 mM NaCl, 50 mM Tris (pH 7.5) and 2 mM EDTA), containing 
phosphatases (Sigma-Aldrich, Saint Louis, Missouri, USA) and proteases (Roche Applied 
Science) inhibitors, incubated on ice for 15min followed by centrifugation (14000 rpm, 15’, 
4°C) and collection of the supernatant. Proteins were quantified using a Bradford protein 
assay (BIO RAD, CA, USA) (BSA [AppliChem, Darmstadt, Germany] standards: 250, 500, 
750, 1000, 1500 and 3000μg/mL). The absorbance change was read in at 655nm in 
microplate reader (BIO RAD, CA, USA). Standard curves were accepted for an r2 >0.98. 
Protein from the cell extracts,  denaturated with 4x loading buffer ( 5min, 95oC), were 
resolved by sodium dodecyl sulphate (SDS)-PAGE with a gel 40% bisacrylamide 29:1 
(BIO RAD, CA, USA) concentration of 12% or 16%  (v/v) at 100V for 2.5 hours. Loaded 
volumes of each input were determined so that the applied protein mass was the same for 
each lane (60-80μg). Proteins were, then, electrotransferred onto a Hybond ECL 
nitrocellulose membrane (GE, Healthcare, UK) for 1.5 hours at 120mV or 500mA. 
After staining the membrane with Ponceau S dye (Sigma-Aldrich) to check the 
uniformity and overall effectiveness of protein transfer from the gel to the membrane, 
membranes were blocked for 30 minutes at room temperature (RT) in PBS1x containing 
0.5% (v/v) Tween-20 (Sigma-Aldrich, Saint Louis, Missouri, USA) (PBS-T) and 5% (w/v) 
low-fat dry milk. Incubation with primary antibodies, diluted in PBS-T containing 0.5% 
(w/v) low-fat dry milk (except when stated differently) was carried out according to the 
manufacturer’s instructions (see conditions in Table III) with gentle agitation. Membranes 
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were then washed with PBS-T (5 times, 5 minutes each) and subsequent incubation with 
suitable horseradish peroxidase conjugated secondary antibody diluted 1:2000 in the above 
solution was performed for 1h at room temperature. Membranes were washed again (once 5 
minutes and 3 times 10 minutes) and then bands were visualized by chemiluminescence 
using the ECL detection system (Perkin-Elmer, California, USA). 
Later, protein expression was quantified using the Bio-Rad quantity One 1-D 
Analysis software (BIO RAD, CA, USA) and normalized by the levels of β-actin. 
Table III - Antibodies used and respective conditions used in the procedures of Western Blot. 
Protein Dilution Incubation Animal 
origin 
Molecular 
weight (kDa) 
Commercialized by 
GRIM-19 
 
1:1000 
(milk 5%) ON;4oC mouse 17 
Abcam 
STAT3 
1:1000 
(milk 5%) 2h;RT rabbit 79.86 
Cell Signaling 
Technologies, Inc. 
p-STAT3 
Tyr705 
1:1000 
(BSA 5%) ON;4oC rabbit 79.86 
Cell Signaling 
Technologies, Inc. 
p-STAT3 
Ser727 
1:1000 
(BSA 5%) ON;4oC mouse 86 
Cell Signaling 
Technologies, Inc. 
HK II 
1:800 
(BSA 5%) 2h; RT rabbit 102 
Abcam 
GLUT1 
1:400 
(BSA 5%) ON;4
oC rabbit 55 
Abcam 
COX II 
1:1000 
(milk 5%) ON;4oC mouse 22 
MitoSciences 
H1 
1:500 
(milk 5%) ON;4
oC mouse 32 
Santa Cruz 
Biotechnology 
β-actin 
1:2000 
(milk 5%) 1h; RT goat 44 
Santa Cruz 
Biotechnology 
 
HKII – Hexokinase II; GLUT1- Glucose transporter 1; COX II- Cytochrome C oxidase subunit II; H1- Histone 1; ON- Overnight. 
 
 
 
 
3.7 Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) 
  
RT-PCR was performed in two steps. The first was to perform the reverse 
transcription reaction, obtaining the cDNA from de mRNA. Posteriorly, conventional PCR 
was performed using cDNA obtained from the first step. 
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The cDNA synthesis was performed with 1μg of RNA, using 100µM random 
hexamer primer (Fermentas, Lisbon, Portugal ), 220U RevertAidTM Reverse Transcriptase 
(Fermentas), 5x reaction buffer (Fermentas), 20U RiboLockTM RNase Inhibitor 
(Fermentas) and 40mM dNTPs mix (Bioron GmbH, Germany), to a final volume of 20μL. 
The thermal cycling conditions were 10 min at 25ºC, followed by 60 min at 42ºC and 
finally 10 min at 70ºC. The reactions were performed on a Bio-Rad MyCyclerTM Thermal 
Cycler (BIO RAD, CA, USA). A negative control was included to detect possible RT-PCR 
contamination. 
PCR reaction was performed as described previously in this manuscript (see section 
3.3.1). Details of the forward and reverse primers (Invitrogen, UK) used to amplify GRIM-
19 cDNA (exon1to 5) are available in table IV. A negative control was included in each 
PCR reaction, in order to detect possible PCR contamination. A positive control was used to 
access the RT reaction: actin amplification was used with this purpose. 
Table IV- Primers sequences to amplify cDNA of GRIM-19 and β-actin and their length and annealing 
temperature. 
F, FW- forward primer; R- reverse primer 
 
 
 
3.8 Real-Time PCR / qPCR 
 
 
Total RNA was extracted from cells using Trizol method (Invitrogen), DNA removal 
using DNase I (Fermentas Life Science, Portugal), followed cDNA conversion (BIO RAD, 
CA, USA), according to manufacturer´s instructions.  
Real-time PCR was performed to quantify GRIM-19 and STAT3 mRNA in the cell 
lines. The reaction was also performed according to manufacturer’s instructions using the 
RT2 Real-TimeTM SYBR Green/ROX PCR master mix (Qiagen, Hilden, Germany) , whose 
mastermix contains a high-performance HotStart DNA Taq polymerase, nucleotides and 
ROX (when needed to normalize a specific instruments’ optics). Two housekeeping genes 
were used as control, β-actin and HPRT (primers already available in our lab). Primer 
sequences are described in table V. 
Primer Name Sequence (5’-3’) Amplicons size (bp) 
Annealing 
Temperature 
(ºC) 
GRIM 1F ATGGCGGTGGCAGTAAGTCAC ~492 58 
GRIM19 RNAR CTA CGT GTA CCA CAT GAA GCC GT 
B_ACTIN FW CTT CCT TCC TGG GCA TGG AGT C 155 58 
B_ACTIN RW CTT CTG CAT CCT GTC GGC AAT G 
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 Each sample was efficiency-corrected against a standard curve, for each target 
(GRIM-19/STAT3 and β-Actin/HPRT). Afterwards, samples were normalized to an 
endogenous control (β-Actin/ HPRT) to ensure that expression levels were correctly 
compared among each other. Those two parameters ensure that samples are standardized, 
compared and analyzed correctly. 
 
                           Table V- Primers sequences used to perform Real-Time PCR. 
Primer Name Sequence (5’-3’) 
GRIM19EXPF TAC AGC ATG CTG GCC ATA GGG AT 
GRIM19EXPR AGG TTC TCC CGA AGC ATC TGC AA 
STAT3RTF TGT GGG AAG AAT CAC GCC TTC TAC 
STAT3RTR GTC ATC CTG GAG ATT CTC TAC CAC 
B_ACTIN FW CTT CCT TCC TGG GCA TGG AGT C 
B_ACTIN R CTT CTG CAT CCT GTC GGC AAT G 
HPRT1- FW GCAGACTTTGCTTTCCTTGGTCAG 
HPRT1-R GTCTGGCTTATATCCAACACTTCGTG 
           F, FW- forward primer; R- reverse primer 
 
3.9 GRIM-19 gene promoter analysis 
        3.9.1    Evaluation of methylation status  
Gene silencing by hypermethylation of specific genes promoter is a well-known 
feature of neoplastic cells and plays an important role in normal cell differentiation and 
development. DNA methylation occurs mainly at CpG dinucleotides and involves the 
enzymatic addition of a methyl group to the cytosine residue, without changing the primary 
DNA sequences.  As GRIM-19 is downregulated in several tumors we intended to do a 
primary evaluation of the methylation status of GRIM-19 promoter. To accomplish this we 
used an easily and reliable assay the  EpiTec Methyl qPCR assay (Qiagen, Hilden, 
Germany) which associates two techniques: digestion using methylation-sensitive and a 
methylation-dependent restriction enzyme + quantification of remaining DNA by Real-
Time PCR (qPCR) using predesigned primers  to detect the methylation status of the 
GRIM-19 gene promoter region. This experience was performed according to 
manufacturer’s instructions (EpiTect® Methyl qPCR kit, Qiagen, Hilden, Germany). Then, 
results were analyzed according to the kit instructions (see details in Annex II). 
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         3.9.2   Treatment with a DNA demethylating agent, 5-aza-2’-deoxycytidine 
According to manufacturer’s description (Sigma-Aldrich, Saint Louis, Missouri, 
USA), 5-aza-2'-deoxycytidine (5Aza-dC) is an epigenetic modifier that inhibits DNA 
methyltransferase activity. This results in DNA demethylation and gene activation by 
remodeling "opening" chromatin (Figure 7). The remodeling of the chromatin structure 
allows transcription factors to bind the promoter regions, assembly of the transcription 
complex and gene expression. 
 
3.9.2.1 Determination of the ideal concentration of 5-aza-2'-deoxycytidine 
          Prior to the demethylation treatment we tested the ideal concentration of 5-aza-2'-
deoxycytidine (5Aza-dC) to be used. Thus, 1.5x104 cells (786-O and Caki-2) were plated in 
a 6-well culture plate and maintained at 37ºC for approximately 7hoursto allows cell 
adhesion. After this period, medium was replaced with different concentrations of 5Aza-dC 
(1; 2.5; 5 and 10µM from stock of 2.2 mM 5Aza-dC in DMSO). Additionally, one well was 
maintained in normal cell culture conditions and other with DMSO 10µM (vehicle) as 
controls. Cells were maintained in these conditions during 4days by controlling confluence 
and cell death. Thereby, we selected 5µM of 5Aza-dC as the ideal concentration to be used. 
 
  3.9.2.2 Demethylation treatment of DNA  
 A total of 1.0x105 cells (786-O and Caki-2) were plated in cell culture dishes. After 
cell adhesion, cells were incubated with 5µM of 5Aza-dC (Sigma-Aldrich, Saint Louis, 
Missouri, USA) for 4days in normal cell culture conditions (at 37°C, 5% CO2). Controls 
were prepared as referred above. After 4days, cell pellets were obtained for extraction of 
nucleic acids and for protein lysates, as mentioned before (see 3.2 and 3.6). 
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Figure 7. Deoxynucleoside analogues such as 5-aza-2'-deoxycytidine (depicted by Z) are converted into 
the triphosphate inside S-phase cells and are incorporated in the place of cytosine into DNA. 
Ribonucleosides (5-azacytidine) are reduced at the diphosphate level by ribonucleotide reductase for 
incorporation (not shown). Once in DNA, the “false bases” form covalent bonds with DNA 
methyltransferases (DNMTs), resulting in the depletion of active enzymes and the demethylation of 
DNA. Pink circles, methylated CpG; cream circles, unmethylated CpG (adapted from [99]).   
 
 
3.9.3   Bisulfite conversion and cleanup of converted DNA   
         This procedure was performed using EpiTect® Bisulfite kit (Qiagen, Hilden, 
Germany) following sequencing reaction. As referred previously, methylation of DNA 
usually occurs in cytosine residues, especially in CpG dinucleotides in small regions of 
DNA, known as CpG islands.Those are usually clustered to the regulatory region of the 
genes (like the promoter). With bisulfite conversion of the DNA, the unmethylated 
cytosines are converted into uracil, while methylated cytosines do not suffer any change. By 
this way, it is possible to determine different DNA sequences for methylated and 
unmethylated DNA which allows to conclude if DNA is methylated by comparison with 
sequence of non-treated DNA (Figure 8). 
First of all, the primer sequences (forward and reverse) were designed based in 
GRIM-19 promoter sequence (see Annex III). The primers were constructed to anneal to a 
region without CGs otherwise it can be altered by the bisulfite conversion, which could 
modify or even prevent the annealing of the primers to the DNA.  
In table VI are described the primer sequences and the size of the PCR product. Two 
negative controls were included in each PCR reaction, in order to detect possible PCR 
contamination by bisulfite treated DNA and to test the specificity of primers in the 
amplification of the treated DNA. 
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After PCR optimization, bisulfite conversion and cleanup of converted DNA was 
performed by EpiTect® Bisulfite kit (Qiagen, (Hilden, Germany) according to the 
manufacturer’s). Then, extracted DNA was quantified as previously mentioned. To check if 
any bisulfite converted DNA was amplified in the PCR, an electrophoresis in agarose gel 
were perfomed: if it was observable a band in the agarose gel thus it was extracted, DNA 
purified and a sequencing reaction was performed, as described in 3.3.1, 3.3.3 and 3.4, 
respectively.  
 
Figure 8. Bisulfite sequencing protocol. DNA is treated with bisulfite resulting in the conversion of 
cytosines into uracils, while methyl-cytosines remain untouched. After sequencing, treated sample shows 
that methylated cytosine (mCG) remains unaltered at the C lane while unmethylated cytosine converted 
into thymine (uracil was substituted by thymine during DNA sequencing (adapted from [100]). 
 
Table VI- Primers sequences for methylated DNA, their correspondent product size. 
Primer Name Sequence (5’-3’) 
Amplicons 
size (bp) 
Grim19_MET_Prom-1F TGTTTAGGTTTGGGTAGTTATGGGTT 
435 
Grim19_MET_Prom-1R CCAAAATAAAAATAACCACATCCAAAAAATACAA 
Grim19_MET_Prom-2F TTGTATTTTTTGGATGTGGTTATTTTTATTTTGG 
509 
Grim19_MET_Prom-2R AACTAAATACATAATATTAAAAAACAACTACTACT 
Grim19_MET_Prom-3F AGTAGTAGTTGTTTTTTAATATTATGTATTTAGTT 
253 
Grim19_MET_Prom-3R ACTAAAAAATCTTTACTCCTCTTTTACC 
Grim19_MET_Prom-4F GGTAAAAGAGGAGTAAAGATTTTTTAGT 
339 
Grim19_MET_Prom-4R CTAAAACCCCAACACAAAATAA 
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3.10 Membrane potential (JC-1) 
 
Maintenance of mitochondrial function and integrity requires an inside-negative 
potential difference across the mitochondrial inner membrane. This potential is sustained by 
the electron-transport chain (ETC). 
In order to compare possible differences of mitochondrial membrane potential (ΔΨm) 
between the described cell lines, we used JC1 Mitochondrial Membrane Potential Assay Kit 
(Mitosciences, Abcam, Cambridge, UK), following manufacturer’s instructions. 
In addition to this procedure, we also evaluated the effect of a well-known inhibitor 
of MRC Complex I, called rotenone (Sigma-Aldrich, Saint Louis, Missouri, USA), in the 
ΔΨm by exposing same cells to a gradient of rotenone concentrations (5, 10 and 20µM) 
during 4hours at 37ºC. DMSO was used as the vehicle (control). Each experiment was done 
twice. 
 
3.11 Cell fractionation assay - cytosolic, mitochondrial and nuclear proteins 
The main purpose of the cell fractionation assay is to measure proteins of interest 
differentially represented in the cytosol, mitochondria and nuclei and is particularly 
interesting to study possible translocations of the proteins between these three cellular 
compartments.  
         Therefore, 4.0x104 cells of each cell line were maintained in 6-well culture plate 
during 48hours. Total cell lysates (WCE) were performed at the same time as control for 
subsequent (WCE) Western blot analysis.  
          For subcellular protein fractionation, the Standard Cell Fractionation Kit from 
Mitosciences (Abcam, Cambridge, UK) was used, according to manufacturer’s instructions.  
Then, samples were frozen at -80oC until be used for analysis. Proteins of the cytosolic, 
mitochondrial, nuclear and total fractions were prepared for Western blot analysis as 
mentioned before. The primary antibodies for STAT3 and p-STAT3, GRIM-19 and β-actin 
were the same as used for others Western blot. Additional antibodies used as nuclear, 
mitochondrial controls were, respectively: H1 and COX II. Actin was used as cytosolic 
control (see all conditions in table III). Secondary antibodies (1:2000) (anti-rabbit, anti-
mouse and anti-goat) conjugated with peroxidase were from Santa Cruz BT and bands were 
visualized by the ECL detection system (Perkin-Elmer, California, USA). 
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3.12 Immunofluorescence- cytoskeleton, mitochondrial and nuclear staining 
In order to immunostain cells at a cytosolic, mitochondrial and nuclear level, α-
tubulin, Mitotracker (a probe that selectively stains mitochondria) and DAPI were used, 
respectively, for a better morphological characterization of the cell lines. 
Cells (5.0x 104) were cultures on glass coverslips in 6-well plate during 24hours. 
After incubation with 250nM CMXRos (Mitotracker Red) (Molecular Probes) for 30min, at 
37oC, cells were fixed with 3.7% formaldehyde for 30min at room temperature (RT). After 
wash three times with PBS 1x, the fixed cells were blocked with a solution of NH4Cl 50mM 
for 10min at RT. After washes, cells were permeabilized with 0,2% Triton X-100 for 5min 
at RT. Primary antibody polyclonal anti- α-tubulin (1:5000)( Sigma-Aldrich Saint Louis, 
Missouri, USA) was incubated for 1hour and then washed three times with PBS 1x. Then 
cells were incubated during 45min with Fluorescein isothiocyanate (FITC)-conjugated 
rabbit anti-mouse secondary antibody (1:1000) (Dako, Lisbon, Portugal) to recognize the α-
tubulin epitope. After three times washes with PBS1x, the coverslips were mounted with 
DAPI + Vectashield (1:1) (Vector Laboratories). The cells were examined in a fluorescence 
microscopy. 
 
3.13 In vitro cellular growth assay using BrdU incorporation assay 
To evaluate cellular proliferation in the described cell lines, replicated DNA strands 
were labeled using BrdU (5-Bromo-2'-deoxyuridine) (Sigma-Aldrich, Saint Louis, 
Missouri, USA). Basically, BrdU (a thymidine analog) is specifically incorporated into 
DNA, in place of thymidine, during DNA synthesis. Then, anti-BrdU antibody conjugated 
with a fluorochrome is used to identify cells that have incorporated BrdU for 
immunochemical analysis of cell proliferation. 
A total of 4.0x104 cells from each cell line were plated in a well of 6-well plate, 48 
hours prior to the experiment. Then the cell culture medium was removed and replaced with 
the diluted labeling solution (2µL/mL). After 2h of incubation with 10 μM BrdU (Sigma-
Aldrich) in the culture medium at 37oC, cells were tripsinized, centrifuged (1200rpm,5min), 
washed with PBS1x and then fixed with 4% paraformaldehyde (PFA). After removal of the 
PFA, cells were resuspended in PBS 1x (when necessary samples were stored at 4ºC until 
next step). Then, cytospin were prepared by centrifugation of 150µL (adjusted to cells 
confluence) of labeled cells (500 rpm, 5min) directly onto cleaned slides. A square were 
delimited around cells using a hydrophobic pen (Dako, Glostrup, Germany).  
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 Before and after, cells were incubated with 2 M HCl for DNA denaturation, washed 
three times with PBS1x and two additional washes with 0.05% BSA + 0.5% Tween 20 in 
PBS1x prior to the first incubation. Then, cells were incubated 1h with the primary anti-
BrdU antibody (Dako, Glostrup, Denmark; 1:10 dilution in 0.05% BSA + 0.5% Tween 20 
in PBS), washed and incubated 1 h with the secondary anti-mouse antibody conjugated with 
FITC (Dako; 1:100 dilution in 0.05% BSA + 0.5% Tween 20 in PBS). The nuclei were 
counterstained with DAPI (Vector Laboratories) and the slides were mounted in 
Vectashield mounting medium (1:1) (Vector Laboratories). Immunostained cells were 
observed using fluorescence microscopy. BrdU and DAPI positive cells were counted using 
Image J (a Java-based image processing programme). Results were expressed as the ratio of 
BrdU- to DAPI-positive cells. 
 
3.14 In vitro cell death assay using TUNEL assay 
To evaluate and quantify cell death in the described cell lines, DNA strand breaks 
were labeled using TUNEL assay (“In situ cell death detection kit, fluorescein” [Roche, 
Mannheim, Germany]). 
TUNEL (Terminal deoxynucleotidyl transferase-mediated d-UTP Nick End Labeling 
assay) is based in one of the hallmarks of apoptosis, the activation of endonucleases that 
cleave chromosomal DNA preferentially at internucleosomal. TUNEL assay is based on 
labeling of DNA stand breaks (and not only single-strand breaks) with modified nucleotides 
- fluorescein-dUTP -, in a reaction catalysed by the exogenous enzyme terminal 
desoxynucleotidyl transferase. This assay has the advantage of revealing early DNA 
sections breaks during apoptosis, prior to the loss of any significant DNA content. 
However, the presence of DNA strand breaks is not unique to apoptosis, although it marks 
preferentially apoptosis. To clearly discriminate apoptosis from other forms of cell death, 
this assay should be run together with other methods to show the specificity of the 
measurement [101]. As a result, this method was regarded as a cell death assay. 
Total of 4.0x104 cells from each cell line were plated in a well of 6-well plate, 48 
hours prior to the experiment. Firstly, the cell culture medium were removed and saved (as 
it contain majority of died cells). Cells were tripsinized and mix with others in the “saved 
medium”, centrifuged (1200rpm, 5min) and washed with PBS 1x. Then, cells were fixated 
using 4% PFA (30min, RT).After remove PFA cells were resuspended in PBS (when 
necessary samples were stored at 4ºC until next step). 
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Cytospins were prepared as abovementioned in BrdU assay and cells were 
permeabilized with a solution of 0.1%Triton X-100 in 0.1% sodium citrate dehydrate. Then 
cells were labeled with TUNEL reaction mixture (“In situ cell death detection kit, 
fluorescein” [Roche (Mannheim, Germany)]). As negative control, we used a reaction 
mixture without the enzyme that catalysis polymerization of labeled nucleotides to free 3’-
OH DNA ends. The nuclei were counterstained with DAPI (Vector Laboratories) and the 
slides were mounted with Vectashield mounting medium (1:1) (Vector Laboratories). 
Immunostained cells were observed by fluorescence microscopy. TUNEL and DAPI 
positive cells were counted using Image J (a Java-based image processing programme). 
Results were expressed as the ratio of TUNEL- to DAPI-positive cells.  
 
 
3.15 Glucose and lactate quantification  
 
To have a general picture of the metabolism of the aforementioned cell lines and their 
clones, we measured the levels of glucose and lactate in the culture medium. 
The medium from 1.5x104 cells of each cell line growing in 12-well culture plate was 
collected and frozen at -80ºC until the time of measurement. This procedure was done 72h 
after the seeding. At the same time, cells were counted using Z Series Particle Count and 
Size Analyzer (Beckman Coulter).   
Glucose content in the culture medium was quantified using Glucose GOD/PAP Kit 
(Roche, Mannheim, Germany) and subtracted to the initial concentration present in the 
respective fresh medium used to maintain each cell line. Lactate was quantified with LO-
POD enzymatic colorimetric assay (Spinreact, Girona, Spain) also normalizing the values 
for a sample of culture medium where no cells was cultured. 
 
3.16 Statistical analysis 
Whenever adequate, the results are presented as mean ± SEM. Statistical analysis was 
done in GraphPad Prism 5, using Student's t-test; Two-way ANOVA and One-way 
ANOVA with Bonferroni and Tukey post-hoc test, respectively. Results were considered 
statistically significant when p<0.05 (*, p<0.05; **, p<0.01;***, p<0.001). 
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Results of this master thesis will be divided in three main parts according to the three 
main questions previously mentioned. 
 
4.1 The role of GRIM-19 in the renal tumorigenesis 
4.1.1 GRIM-19 and clear cell renal cell carcinoma cell lines - a model of study 
According to the evidences that GRIM-19 may play a crucial role in the renal 
tumorigenesis, in this work we used clear cell renal cell carcinoma (ccRCC) cell lines as a 
model. Thereby, the first task of this work was to evaluate GRIM-19 expression in the two 
following cell lines: Caki-2 and 786-O. 
By Western blot we observed significant differences between them: Caki-2 cell line 
shows a 2-fold increased expression of GRIM-19 protein in comparison with 786-O cell 
line, as shown in figure 9A and 9B. 
 
 
 
 
 
Figure 9.  GRIM-19 protein expression in two cell lines derived from clear cell renal cell carcinoma 
(Caki-2 and 786-O). A- Western blot analysis of GRIM-19 expression and β-actin as an endogenous 
control. B- Representative quantification of GRIM-19 expression. Data are expressed as density of 
GRIM-19 band per the density of β-actin band. Columns, score mean.  
 
Interestingly, the morphology of the cell lines is also distinct. Caki-2 cells have a 
more circular shape and smaller size than cells of 786-O cell line which have an oval shape 
and a larger cytoskeleton. Moreover, 786-O cell line, which expresses less GRIM-19 
protein, seems to have a different pattern of mitochondrial network (Figure 10). 
A B 
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Figure 10. Nucleus and cytoskeleton were labeled with DAPI (blue) and α-tubulin primary antibody and 
FITC-conjugated secondary antibody (green), respectively. Mitochondria were labeled with Mito-Tracker 
Red CMXRos (red). Merged images are shown (magnification, x63). 
 
These initial observations/characterization gave rise to additional questions that we 
try to answer in the following sections, particularly in the last section related with GRIM-19 
gene promoter. 
 
4.1.2 Molecular analysis of GRIM-19 gene 
Since, in our lab, PCR conditions were already optimized to amplify GRIM-19 gene, 
after DNA extraction of Caki-2 and 786-O cell lines (as aforementioned), we performed 
PCR for the five exons of GRIM-19 in order to know if alterations at DNA level may 
explain the difference in GRIM-19 expression in the two cell lines in study. After 
amplification, PCR products were run on a 2% agarose gel (Figure11) to check for the 
presence, quality and integrity of the fragments.  
PCR products were then sequenced but the coding region of this gene was found to 
harbour no mutations, indicating that the downregulation of GRIM-19 observed in 786-O 
cell line comparing with Caki-2 cell line was not a consequence of mutations. 
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Figure 11. 2% Agarose gel showing the PCR products of exon 1 (352 bp), exon 2 (205 bp), exon 3 (150 
bp), exon 4 (222 bp) and exon 5 (261bp) of GRIM-19 from two clear cell RCC cell lines (Caki-2 and 786-
O). The negative control was the blank (containing no DNA) and the molecular weight marker. 
 
Possible alterations at transcriptional level were evaluated by studying GRIM-19 
mRNA. Total RNA was extracted from 786-O and Caki-2 cell lines and RT-PCR was 
performed in order to check for GRIM-19 expression. Evaluation of β-actin mRNA 
expression was used as a control (155 bp). 
 As shown in figure 12, these two cell lines expressed a normal transcript of GRIM-
19 (exon 1 to 5, approximately 492bp), showing that the distinct expression of GRIM-19 in 
these cell lines is not explained by a proposed alternative splicing by He and Cao [102]. 
 
Figure 12. RT-PCR products for GRIM-19 (492 bp) and β-actin (155bp) of ccRCC cell lines (Caki-2 
and 786-O) and a control of RT-PCR (RT negative). 
 
In addition, we quantified GRIM-19 mRNA by perfoming Real-Time PCR in order to 
confirm that Caki-2 cells express more GRIM-19 protein than 786-O cells. RNA was 
extracted from referred cell lines and RT-PCR was performed to produce GRIM-19 cDNA 
from 1000ng of RNA.  
Notice that with this first Real-Time PCR experience we also intended to optimize 
ideal conditions mainly cDNA concentration. Using different cDNA concentrations, we can 
confirm that Caki-2 cells have a significantly higher expression of GRIM-19 mRNA than 
786-O cells (Figure13). 
  
 
52 
 
Figure 13. Real-Time PCR results for GRIM-19 in Caki-2 and 786-O cell lines. Data is normalized 
for β-actin expression. The error bars represent the mean ± SEM (n = 2). The asterisks indicate the level 
of statistical significance: ***, p < 0.0001; according to one-way ANOVA and a posterior Tukey test. 
 
  These results suggest that the differences in GRIM-19 protein expression between 
Caki-2 and 786-O are not explained by mutations  or alterations at transcriptional level but 
may be due to  other regulatory mechanism contribute to loss/downregulation of GRIM-19. 
 
4.1.3 Analysis of tumor cell lines with stable knockdown of GRIM-19 
One of the main purposes of this work was to evaluate the effect of GRIM-19 
silencing in renal tumorigenesis. This was accomplished by knocking down GRIM-19 
through the use of short hairpin RNA (shRNA). With this experiment in vitro we could 
simulate the downregulation of GRIM-19 previously observed in immunohistochemical 
assays in thyroid and kidney tumors performed in our lab (unpublished data) and analyze 
the interaction between GRIM-19 and STAT3. 
Firstly, Caki-2 cell line was transfected with four different plasmids plus two control 
vectors. The selection with culture media containing 2μg/mL puromycin was started 
24hours after transfection. Unfortunately, after several weeks no clones were obtained from 
Caki-2 shGRIM-19. 786-O cell line reverse transfection was initiated with same procedure 
as previously mentioned. After approximately three weeks of selection, we observed the 
first isolated clones from different shGRIM-19 plasmids. Each clone grew and formed a 
single colony; stable cell lines were achieved by picking clones from the cells transfected 
with the different plasmids (identified with plasmid number: 89, 90, 91, 92 and controls: 
TR2 and TR3 respectively; clones derived from same plasmid were distinguish by letters: 
A, B, C, D plus number if picked twice from some clone). From this experience we 
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achieved a total of 14 isolated clones which were maintained in culture; samples from each 
clone were frozen until silencing confirmation.  
A new attempt of Caki-2 shGRIM-19 was performed; even though three isolated 
clones were obtained, no clones from shGRIM-19 controls were obtained. However, the 
silencing of GRIM-19 in these three Caki-2 shGRIM-19 clones were also analyzed together 
with above fourteen clones of 786-O shGRIM-19 by Western blot (Figure 14A). In order to 
do a more reliable selection of the clones with better knockdown of GRIM-19 expression, 
immunoblots represented in figure 16A were quantified and normalized to β-actin 
expression (Figure 14B).Comparing mean expression between Caki-2 and its shGRIM-19 
cell lines, at least Ti92B presents almost half of GRIM-19 expression but without a Caki-2 
shGRIM-19 control it is not possible to do further experiments. However, from 786-O 
shGRIM-19 there are three clones with successful GRIM-19 silencing (89A2, 90B and 
90C). Among the 786-O shGRIM-19 controls, TR2A was the selected control (scrambled 
vector) as it has similar GRIM-19 protein expression as 786-O cell line.  
 Despite Caki-2 unsuccessful reverse transfection of GRIM-19, this cell line will 
continue to be considered in subsequent assays as a control with normal expression of 
GRIM-19 protein.  
After this first basic screen of the GRIM-19 silencing, cell lysates were used for 
Western blot analysis with an antibody against GRIM-19 to perform a semi-quantification 
and verify the functionality of the shRNA vectors.  
Densitometric analysis shown approximately 30%, 60% and 90 % reduction of 
GRIM-19 protein expression in comparison to scrambled vector, TR2A (Figure15 B). The 
results indicate that shRNA-GRIM-19 was specific and efficient for GRIM-19 gene 
silencing in 786-O cell in vitro (Figure 15A and 15B). 
Ideally, to reconfirm if the abovementioned clones have effectively knockdown of 
GRIM-19 expression, frozen samples of same cell lines were then thawed and maintained in 
culture and cell lysates were used to perform Western blot analysis. However, the 
freeze/thaw procedure seems to affect efficiency of shGRIM-19 as shown in immunoblot 
(Figure 16A) and respective densitometric analysis (Figure 16B). From that we can 
observed that 90C 786-O shGRIM-19 cell line is not silenced comparing with the scrambled 
(TR2A) and 90B and 89A2 presents an increase GRIM-19 expression (Figure 16A and 
16B) comparing with initial analysis (Figure 15B). 
 
 
  
 
54 
BA 
 
Figure 14. Analysis GRIM-19 silencing in Caki-2 and 786-O cell lines and their shGRIM-19 clones. 
A-Western blot analysis of GRIM-19 expression and β-actin as an endogenous control. B- Representative 
quantification of GRIM-19 expression, data are expressed as density of GRIM-19 band per the density of 
β-actin band. Red arrows are highlighting selected 786-O shGRIM-19 clones with better knockdown of 
GRIM-19 and also the selected shGRIM-19 control. Columns, score mean. 
 
 
 
 
 
 
 
Figure 15. GRIM-19 silencing using a plasmid expressing the shRNA in 786-O cell line: shRNA for 
GRIM-19 90B, 90C and 89A2, in comparison with the scrambled control TR2A, effectively diminished 
GRIM-19 protein levels. A representative immunoblot is shown.  
 
 
A 
B 
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Figure 16.  Reanalysis of GRIM-19 protein expression in selected 786-O shGRIM-19 clones. A-
Western blot analysis of GRIM-19 expression and β-actin as an endogenous control. B- Representative 
quantification of GRIM-19 expression, shRNA for GRIM-19 90B, 90C and 89A2, in comparison with the 
scrambled control TR2A, effectively shRNA efficiency were altered as observed by GRIM-19 protein 
levels. 
 
Thereby we decided to evaluate whether time in culture and cell confluence affects 
GRIM-19 expression of our cell lines (Caki-2 and 786-O) and 786-O shGRIM-19 clones 
(90B, 89A2, 90C and scrambled, TR2A)  to conclude which is the optimal cell culture 
conditions to GRIM-19 expression. We observed that GRIM-19 expression is affected by 
cell culture conditions, namely the duration of cell culture, as it is shown in figure 17a and 
17b. Notice that even cells that have been in culture during a short period of time present a 
less efficient GRIM-19 silencing after 72hours in cell culture. 
 
 
 
 
 
 
 
 
 
 
Figure 17. Evaluation of cell culture conditions influence in GRIM-19 protein expression. a- 
Western blot analysis of GRIM-19 expression in A: lysates from cells in culture and B: new lysates of 
same frozen cells after 24, 48 and 72hours in cell culture. b- Representative quantification of GRIM-19 
expression normalized by respective β-actin expression after 48 and 72hours. 
B 
a b 
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In general, either lysates from cells in culture or new lysates of same frozen cell lines 
shown to have a more efficient GRIM-19 silencing around 48hours. Therefore, all further 
experiences with these cell lines will be performed no more than 48hours after seeding. 
 
4.1.4 Cell lines characterization 
4.1.4.1 786-O cell line and shGRIM-19 clones 
After selection of cell lines from shGRIM-19 clones, we aimed to better characterize 
them in a morphological and functional level.   
 
 Regarding morphological analysis, microscopic pictures or immunofluorescence 
observations showed that shGRIM-19 clones present an irregular cellular size (presence of 
small and large cells) in comparison with scrambled (TR2A) and 786-O parental cell line 
(Figure 18 and 19). Figure 18D represents an amplification of a large cell from the clone 
89A (786-O shGRIM-19). This is a particular aspect observed several times among 
shGRIM-19 clones.  
 
Figure 18.  Morphological analysis of a shGRIM-19 clone in comparison with scrambled (TR2A) and 
parental cell line 786-O. A, B, C- magnification 10x; D, E, F- magnification 40x. 
 
Moreover, by immunofluorescence it was possible to visualize a different pattern of 
mitochondrial network by Mitotracker (red staining) (see Figure 19). Clones with higher 
silencing of GRIM-19 clones (90B) present a more disperse mitochondrial network in 
comparison with control (TR2) and clones with less efficient silencing of GRIM-19 (90C). 
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As referred in literature review, GRIM-19 is also crucial in metabolism and 
OXPHOS. Thus, glycolytic profile of shGRIM-19 clones was evaluated by analyzing 
expression of the glycolytic enzyme, Hexokinase II (HK II) and glucose transporter 
GLUT1. It was observed that the levels of the referred proteins are, in general, higher in the 
786-O shGRIM-19 clones than in the scrambled or parental cell line.  
Although the results among the 786-O shGRIM-19 clones are not homogeneous, 90B, 
one of the most GRIM-19 silenced clones, show a higher expression of HKII and 
interestingly, its GLUT1 expression presents a higher molecular weight (Figure 20A) which 
may mean glycosylation.  
 
 
Figure 19. Immunofluorescence observations comparing 786-O shGRIM-19 clones, scrambled (TR2A) 
and parental cell line, 786-O. Nucleus and cytoskeleton were labeled with DAPI (blue) and α-tubulin 
primary antibody and FITC-conjugated secondary antibody (green), respectively. Mitochondria were 
labeled with Mito-Tracker Red CMXRos (red). Merged images are shown (magnification, x63). 
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Figure 20. Analysis of glycolytic profile of parental cell lines (Caki-2 and 786-O) and 786-O 
shGRIM-19 clones.  A- Western blot analysis of glycolytic proteins expression- glucose transporter 1 
(GLUT1) and Hexokinase II (HK II). B- Representative quantification of glycolic proteins expression 
comparing with GRIM-19 silencing (786-O shGRIM-19). Data normalized to respective β-actin 
expression. Column, score mean.  
Both HKII (catalyzes the first step in glycolysis) and GLUT1 (a glucose transporter 
that increases glucose uptake during glycolysis) are directly related with glucose uptake 
from culture media and lactate production. Therefore, additional assays measuring glucose 
consumption and lactate production were performed to evaluate differences caused by 
GRIM-19 silencing (786-O shGRIM-19). From these assays we concluded that after 
72hours, 786-O shGRIM-19 clones (89A and 90C) have higher glucose consumption and 
increased lactate production in comparison with the scrambled and 786-O cell line (Figure 
21). In comparison with Caki-2, 786-O cell line seems to present differences in relation to 
glucose consumption but it is not statistically significant.  
 
  
 
 
 
 
 
Figure 21. Analysis of glucose uptake and lactate production after 72hours. A- Glucose consumption 
per 106 cells of parental cell lines (Caki-2 and 786-O), 786-O shGRIM-19 clones and scrambled (TR2A). 
B- Lactate production per 106 cells of referred cell lines. The error bars represent the mean ± SEM (n = 
3). The asterisks indicate the level of statistical significance: *, p < 0.05; **, p < 0.01; ***, p < 0.0001; 
according to two-way ANOVA and posterior Bonferroni test.  
A B 
B A 
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Knockdown of GRIM-19 protein expression by shGRIM-19 seems to enhance 
glycolytic phenotype as shown by increase of glycolytic proteins expression and by increase 
uptake of glucose and consequently increased production of lactate. 
The maintenance of mitochondrial function and integrity requires an inside-negative 
potential difference across the mitochondrial inner membrane. This potential is sustained by 
the electron-transport chain (ETC). Taking this into account, we evaluated how GRIM-19 
knockdown could interfere with mitochondrial potential. We used a mitochondrial 
membrane potential (ΔΨm) kit which uses JC-1, a cationic dye that accumulates in 
energized mitochondria. At low concentrations (due to low ΔΨm) JC-1 is predominantly a 
monomer that yields green fluorescence and at high concentrations (due to high ΔΨm) it 
forms dye aggregates yielding a red to orange colored emission. This dye fluorescence 
drops acutely after the addition of the mitochondrial uncoupler, FCCP. Data obtained with 
this assay gives a relative measure of mitochondrial membrane potential as a parameter of 
control and cannot be used for absolute measurements of membrane potential in millivolts. 
By measuring fluorescence of JC-1 aggregates, we could observe a statistically significant 
lower ΔΨm in two out of the three 786-O shGRIM-19 clones (89A and 90C) in comparison 
to the ΔΨm of scrambled (TR2A). Concerning FCCP treatment, there were no statistically 
significant differences but, as shown in figure 22, parental cell lines (Caki-2 and 786-O) and 
scrambled (TR2A) showed a decrease of their ΔΨm. The fact that 786-O shGRIM-19 
clones show a lower basal ΔΨm than Caki-2, 786-O and scrambled (TR2A), may explain 
why their ΔΨm are almost not affected by the ionophore uncoupler of OXPHOS, FCCP. 
Additionally, we analyzed the effect of a gradient of concentrations (5, 10 and 20 
µM) of the well-known inhibitor of complex I of MRC, Rotenone, aiming to understand the 
effect on the ΔΨm of each cell lines. We observed that the parental cell lines and scrambled 
shGRIM-19 control became hyperpolarizated (high ΔΨm) after 5 and 10 µM of rotenone 
treatment; on the other hand, two of the three GRIM-19 silenced clones (90B and 
90C)maintained their ΔΨm, not responding to rotenone treatment.Treatment  with 20 µM of 
rotenone, seems to induce a toxic effect in cell lines with higher basal ΔΨm. Consequently, 
they become depolarized (low ΔΨm) due to disruption of complex I activity. Once more, 
two of the three silenced clones (90B and 90C) maintained their ΔΨm.  
On the other hand, we also have preliminary data that demonstrated decrease cell 
proliferation among 786-O shGRIM-19 clones when compared with controls. Furthermore, 
we have some results of cell death which indicate a similar percentage of apoptosis between 
786-O shGRIM-19 clones and controls. Exceptionally, 90C seems to have the highest 
apoptosis level among all the cell lines. Notice that these two assays are just indicative and 
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it is necessary to perform at least more two experimental replicates to confirm these first 
observations (see Annex IV, Figure A4.1). 
Figure 22. Assessment of mitochondrial membrane potential in situ using JC-1. Effect of FCCP 
(100µM; uncoupler of oxidative phosphorylation) and Complex I inhibitor, Rotenone (5, 10 and 20 µM) 
on ΔΨm in parental cell lines Caki-2and 786-O as well as in scrambled (TR2A) and 786-0 shGRIM-19 
clones (89A, 90B, 90C). Red fluorescence measurement at 590 nm by after 4h treatment was used as an 
index of ΔΨm. The bar graphs show mean fluorescence values of individual cell counts (1.5 × 104 cells) 
and error bars represent the mean ± SEM (n = 2). The asterisks indicate the level of statistical 
significance: *, p < 0.05; **, p < 0.01; according to two-way ANOVA and posterior Bonferroni test. au, 
arbitrary. 
 
Summing up, our results about knockdown of GRIM-19 by shRNA suggest an 
increase of glycolytic activity as shown by analysis of glycolytic proteins and by glucose 
consumption and lactate production assays. Mitochondrial alterations were also observed by 
immunofluorescence assay and by evaluating mitochondrial membrane potential. Indeed 
GRIM-19 silencing induces a reduction of ΔΨm, suggesting a lower mitochondrial activity 
and consequently a lower metabolic efficiency. 
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4.1.4.2 HEK 293 cell line and shGRIM-19 clone 
In addition to the referred tumoral cell lines, in this work we also used a human 
embryonic kidney cell line (HEK 293), with stable downregulation of GRIM-19 protein, to 
compare the results observed in a tumoral (Caki-2 and 786-O) and a non-tumoral (HEK 
293) renal cell line.  
As shown in figure 23A and 23B, HEK 293 shGRIM-19 clone (HEK Ti89) shows 
effective knockdown of GRIM-19 protein expression in comparison to the scramble (HEK 
TR2). Once again, we observe that the efficiency of shGRIM-19 is influenced by cell 
culture conditions. Thereby, all the following experiences with these cell lines were also 
done 48hours after seeding. 
 
 
 
  
 
 
 
Figure 23. Evaluation of cell culture conditions influence in GRIM-19 protein expression. A- 
Western blot analysis of GRIM-19 expression using lysates from cells maintained in culture 24, 48 and 
72hours. B- Representative quantification of GRIM-19 expression normalized by respective β-actin 
expression after 24, 48 and 72hours. Confirmation of GRIM-19 silencing of HEK 293 shGRIM-19 clone 
(HEK Ti89) in comparison with scrambled (HEK TR2).Column, score mean. 
 
From a morphological point of view, no relevant differences were found between 
HEK 293 shGRIM-19 clone and respective controls. However, as it is well-represented in 
figure 24C and 24D, cells from HEK 293 shGRIM-19 clone (HEK Ti89) were always more 
disperse, more individualized in the culture plate than cells from scrambled or parental 
which usually form aggregates of cells ( Figure 24A , 24D and 24B, 24E, respectively). In 
relation with our described tumoral cells, these cells have a particularly to be not so 
adherent thus, easily they detach from the culture plate not allowing successful 
immunofluorescence assays.  
 
B 
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Figure 24.  Morphological analysis of a shGRIM-19 clone (HEK Ti89) in comparison with scrambled 
(HEK TR2) and parental HEK293 cell line. A, B, C- magnification 10x; D, E, F- magnification 40x. 
From the analysis of the glycolic profile of these cell lines, we observed no statistical 
significant differences concerning glucose consumption  and lactate production between 
scrambled (HEK TR2) and shGRIM-19 clone (HEKTi89) (Figure 25A and 25B). However, 
we noticed that the scrambled control (HEKTR2) presented clear differences comparing 
with parental cells, which we attribute to technical problems; we decided not to use the 
scrambled control, but rather compared shGRIM-19 clone with parental HEK 293.  The 
HEK Ti89 clone showed significantly lower lactate production than parental HEK 293 cells, 
while glucose consumption was increased but not significantly (Figure 25).Complementary 
information about glycolytic proteins will be presented in next section of the results.     
 
 
                 
 
 
 
 
Figure 25. Analysis of glucose uptake and lactate production after 72hours. A- Glucose consumption 
per 106 cells of parental cell lines (HEK293), shGRIM-19 clone (HEK Ti89) and scrambled (HEK TR2). 
B- Lactate production per 106 cells of referred cell lines. The error bars represent the mean ± SEM (n = 
3). The asterisks indicate the level of statistical significance: *, p < 0.05; **, p < 0.01; according to two-
way ANOVA and posterior Bonferroni test.  
A B 
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Concerning cell proliferation and cell death preliminary data indicates a similar 
percentage of cell proliferation among three cell lines. HEK Ti89 cell line seems to have 
higher cell proliferation than scrambled but it needs to be confirmed. On the other hand, 
TUNEL results revealed a lower percentage of cell death in HEK Ti89, the clone of 
shGRIM-19.Overall, once again, these two assays are just indicative and it is necessary to 
perform at least more two experimental replicates to confirm these first observations (see 
Annex IV, Figure A4.2). 
In summary, the results from knockdown of GRIM-19 by shRNA in a non-tumoral 
cell line indicate less consistent conclusions than in our tumoral cell line (786-O). From a 
glycolytic point of view, we observed no statistically significant differences in glucose 
uptake but lactate production showed differences, suggesting that the lactate could be used 
by HEK Ti89 as a possible compensatory mechanism. Probably next results could better 
complement this initial evaluation. 
 
 
4.2 GRIM-19 protein expression and STAT3 protein expression, activation and 
localization  
4.2.1 Analysis of GRIM-19 and STAT3 interaction  
It is documented that STAT3 is an intervenient of the GRIM-19 death-inducing 
pathway and that GRIM-19 is a novel inhibitor of STAT3 [40, 41]. However, these findings 
need to be classified in renal tumorigenesis. 
With the purpose of verifying if GRIM-19 silencing induces an increase of STAT3 
expression and activation, we evaluated, by Western blot, STAT3 expression and activation 
by analyzing its total and phosphorylated forms (p-STAT3Try705 and p-STAT3Ser727). 
Our initial results corroborated other studies, since we observed that STAT3 expression and 
its level of activation are higher among 786-O shGRIM-19 clones in comparison with the 
scrambled (TR2A) (Figure 26). 
However, when the same analysis was performed using lysates from cells after 
48hours in culture, the results were not consistent with the initial ones. As shown in figure 
27A, the shGRIM-19 clones show less efficient knockdown, when compared with control. 
However if we compare with parental 786-O cell line, 89A is the clone showing more 
knockdown of GRIM-19 expression. Taking this sample in account, we observed that 
STAT3 total expression is not significant different but that GRIM-19 shRNA seems to 
enhance STAT3 activation as its phosphorylated isoforms show a significant increase of 
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expression comparing to parental 786-O cell line. This result is consistent with our initial 
analysis (Figure 26B) where all shGRIM-19 clones did not present significant differences 
regarding total protein expression of STAT3 but they revealed higher levels of p-
STAT3Try705 and p-STAT3Ser727, the active forms of STAT3. 
 
 
 
 
 
 
Figure 26.  GRIM-19 expression and STAT3 expression and activation. A- Western blot analysis of 
GRIM-19 expression, STAT3 and its isoforms (p-STAT3Try705 and p-STAT3Ser727) and β-actin as an 
endogenous control. B- Representative quantification of expression of the referred proteins in parental 
cell lines (Caki-2 and 786-O) and 786-O shGRIM-19 clones (89A, 90B, 90C) and scrambled (TR2A). 
Results revealed an effective interaction between GRIM-19 and STAT3 expression and activation. 
Knockdown of GRIM-19 expression induces a higher expression and activation of STAT3 in comparison 
with scrambled. Column, score mean. 
Regarding GRIM-19 and STAT3 interaction, in HEK cell lines, we observed that the 
parental, control and silenced cells did not show STAT3Tyr705 expression (Figure 27B). In 
contrast with GRIM-19 shRNA in tumoral cell lines, HEK Ti89 presented a lower 
expression of both STAT3 expression, by STAT3 total protein expression, and activation, 
by p-STAT3Try705 and p-STAT3Ser727 protein expression (Figure 27A and 27B).  
 
 
 
 
 
 
 
 
Figure 27. Reanalysis and analysis of GRIM-19 expression and STAT3 expression and activation in 
A-786-O cell line and its shGRIM-19 clones and B- HEK293 and its shGRIM-19 clone, respectively. 
Lysates from all indicated cell lines were performed 48hours after seeding. 
A B 
B A 
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 We have also analyzed the effects of the variable shGRIM-19 efficiency over the 
levels of HKII and GLUT1.By Western blot analysis we observed that 786-O shGRIM-19 
clones (90B, 89A and 90C) maintain a higher expression of both HK II and GLUT 1 
(Figure 28A). Different results were found in HEK 293 cells since in HEKTi89 (silenced 
for GRIM-19) the levels of HKII and GLUT1 were decreased, when compared with control 
cells. 
 
 
               
                                                                     
Figure 28. Reanalysis and analysis of glycolytic profile by Western blot analysis of glycolytic proteins 
glucose transporter 1 (GLUT1) and Hexokinase II (HK II) in A- parental cell line 786-O and its shGRIM-
19 clones; B- HEK 293 and its shGRIM-19 clone. Data normalized to respective β-actin expression. 
Lysates from all indicated cell lines were performed 48hours after seeding. 
  
 Summing up, GRIM-19 silencing seems to have different effects in tumoral and non-
tumoral cells both in terms of metabolic remodeling and also GRIM-19 and STAT3 
interaction. 
 
4.2.2 Proteins expression and localization – results of cell fractionation assay 
It is clear that is GRIM-19 is a nuclear gene that encodes a mitochondrial protein but 
its localization is still an issue that requires further investigation. Some authors like Máximo 
et al. [48] consider that different localization could reflect the different functions of GRIM-
19 in cellular biology: it can be localized in mitochondria, as part of MRC, or in the 
cytoplasm where it is involved in apoptosis induced by IFN-β /RA and also interact with 
cytosolic proteins, such as STAT3 protein. Moreover, mitochondrial localization and 
function of STAT3 is also a question under investigation. Therefore, we analyzed 
localization of GRIM-19 and STAT3 using a cell fractionation assay which allows to 
analyze mitochondrial, nuclear and cytosolic proteins and their possible translocation 
between these three compartments.  
A B 
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This assay was performed only in the 786-O shGRIM-19 clones that presented more 
efficient GRIM-19 silencing: 89A and 90B.  
The analysis of these results will do not have in account expression levels of proteins 
as this assay was performed using equivalent volumes, as described in manufacturer’s 
instructions. 
GRIM-19 was only found in the mitochondrial and whole cell extraction (WCE) 
fraction, as expected. The minor expression of GRIM-19 in nuclear (Nu) fraction could be 
due to contamination with mitochondrial (Mito) fraction, since COX II (mitochondrial 
marker) was also found in the nuclear fraction at the same level. The same was observed in 
the HEK cell lines. Interestingly, GLUT1, a transporter of glucose located in the 
cytoplasmic membrane, was almost entirely found in mitochondria (Figure 29).  
Concerning STAT3, we found that p-STAT3Ser727 localization was restricted to 
cytosolic and WCE. P-STAT3Ser727 was expected to be located in the Mito fraction but 
the different phosphorylation states of STAT3 could be affected during cell fractionation 
procedure. In the 89A shGRIM-19 clone, the p-STAT3Tyr705 was only present in nucleus 
as it has been described in literature. This observation can be confirmed by histone 1 (H1), 
our nuclear marker (Figure 29A). 
Total STAT3 was mainly located in the cytosolic (Cyto) fraction as it is confirmed by 
cytosolic marker, β-actin (Figure 29A).However, total STAT3 localization also raises the 
hypothesis that p-STAT3Ser727 could be localized in Mito fraction. 
 Parental and silenced clones of HEK293 (Figure 29B) did not express p-
STAT3Tyr705, while p-STAT3Ser727 is located in WCE and Cyto fraction; incubation 
with STAT3 total antibody showed clear evidences of localization in Mito fraction and in 
nuclear fraction.  
The results obtained for 786-O and its shGRIM-19 clones (Figure 29A) coincide with 
observations about HEK cell lines (Figure 29B). In addition, as observed in above analysis 
of Western blot (Figure 27B), we confirmed that HEK cell lines do not express p-
STAT3Tyr705.  
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Figure 29. Cellular localization of proteins: GRIM-19, STAT3 and its active isoforms 
(STAT3Tyr705 and p-STAT3Ser727) and GLUT1. A- The 786-O cell line, the scrambled (TR2A) and 
the 786-O shGRIM-19 clones (90B and 89A) were lysed and fractionated to cytosolic (Cyto), 
mitochondrial (Mito), and nuclear (Nu) fractions. B- Same procedure was performed using HEK293 cell 
line, scrambled (HEK TR2) and shGRIM-19 clone (HEK Ti89).  As a control, protein expression was 
also performed in total cell lysates (or whole cell extraction-WCE). Western blot analysis were performed 
and blots obtained were also probed with anti- COX II as a mitochondrial marker, with anti-Histone 1 
(H1) as nuclear marker and β-actin as cytoplasmic marker. 
 
Notably, from the cell fractionation assay, there are some interesting observations 
which are worth to be discussed in depth such as, GRIM-19 and GLUT1 localization and 
expression of STAT3 in the mitochondrial fraction. 
 
 
A 
B 
  
 
68 
4.3 Study of GRIM-19 promoter  
  
 So far, the results of this work demonstrate that differences of GRIM-19 protein 
expression initially observed in our parental tumoral cell lines, Caki-2 and 786- O, are not 
explained by mutations or alterations in the GRIM19 mRNA transcript. Since many tumor 
suppressor genes are downregulated by DNA hypermethylation during renal tumorigenesis 
[95, 96], we assessed whether GRIM-19 expression is influenced by hypermethylation. 
 
4.3.1. Evaluation of methylation status 
We started by evaluating methylation status of Caki-2 and 786-O cell lines using an 
easy and fast approach, a kit that combine two main techniques: a specific enzymatic 
digestion reaction followed by Real-Time PCR and required data analysis (see Annex II). 
Basically, this kit allows to quantify in a relative manner the hypermethylated fraction 
(FHM) and the unmethylated fraction (FUM) of the GRIM-19 gene promoter. Notice that, 
to date, the GRIM-19 promoter sequence was not known; however this kit was 
commercially available for NDUFA13 (GRIM-19). We used this kit as a preliminary 
analysis being aware that these results could not be completely reliable. After optimization 
of the digestion reaction, we observed that the 786-O cell line shows a higher 
hypermethylated fraction than Caki-2 cell line, as shown in figure 30A, which is consistent 
with the lower GRIM-19 expression. We then decided to treat the two cell lines with a DNA 
demethylating agent, 5-aza-2’-deoxycytidine (5Aza-dC) and analyze the effects on 
GRIM19 expression.  
The ideal concentration of 5Aza-dC was optimized and the cell lines were treated 
with 5µM of 5Aza-dC during 4days. Samples were then prepared for DNA and RNA 
extraction for further analysis. 
The efficacy of the treatment was initially confirmed using again the mentioned kit. 
The results showed that 5Aza-dC demethylation treatment decreased the FHM in both cell 
lines but 786-O cell line showed a more drastic decline of its hypermethylation status 
(Figure 30B). Note that the DNA sample with DMSO (vehicle) treatment was not included 
in this analysis due to a restrict stock of the kit to perform this important initially evaluation 
of 5Aza-dC treatment efficiency.  
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Figure 30. Methylation status of Caki-2 and 786-O. FHM corresponds to hypermethylated fraction and 
FUM corresponds to unmethylated fraction. A- FHM and FUM of both cell lines in normal conditions. B- 
Reevaluation of methylation status after treatment with DNA demethylating agent, 5Aza-dC. The error 
bars represent the mean ± SEM (n = 3). The asterisks indicate the level of statistical significance: *, p < 
0.05; according to Student's t-test. 
  
4.3.2 Quantitative analysis by Real-Time PCR 
We performed Real-time PCR to evaluate if the demethylation treatment enhanced 
GRIM-19 expression. With this analysis we wanted to see, as several other tumor 
suppressor genes in renal cell tumors [97], if GRIM-19 expression is controlled by 
hypermethylation of its promoter (as predicted by above data). 
First we used β- actin as housekeeping gene and we observed that, in contrast with 
our initially hypothesis, with demethylation agent treatment, GRIM-19 mRNA did not 
increase but significantly decreased in Caki-2 cell line (the less methylated) and in 786-O 
cell line there was no significant differences comparing with the respective vehicle (DMSO) 
(Figure 31). 
We also evaluated STAT3 mRNA after 5Aza-dC treatment by Real-Time PCR. The 
primers were designed according with STAT3 gene sequence from ENSEMBLE and tested 
prior to the Real-Time PCR. 
According to several studies, downregulation of GRIM-19 in different type of tumors 
is related with overexpression of STAT3. Thereby observing a decrease in GRIM-19 
expression with demethylation treatment, it is expected to observe an increase of STAT3 
expression if effectively GRIM-19 protein has a capacity to inhibit STAT3 
expression/function.  
A B 
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Figure 31. Real-Time PCR results for GRIM-19 in parental cell lines, Caki-2 and 786-O after 5Aza-
dC treatment. Data is normalized for a standard curve and for β-actin expression. Results correspond to 
3 experimental replicas. The error bars represent the mean ± SEM (n = 3). The asterisks indicate the 
level of statistical significance: ***, p < 0.0001; according to two-way ANOVA and posterior Bonferroni 
test.  
 
Indeed, our results showed that STAT3 mRNA levels are higher in samples treated 
with 5Aza-dC. However those differences were more significant in the786-O cell line 
(DMSO vs 5Aza-dC) where the 5Aza-dC treatment did not affect GRIM-19 expression 
(Figure 32).  
 
Figure 32.  Real-Time PCR results for STAT3 in parental cell lines, Caki-2 and 786-O after 5Aza-dC 
treatment. Data is normalized for a standard curve and for β-actin expression. Results correspond to 3 
experimental replicas. The error bars represent the mean ± SEM (n = 3). The asterisks indicate the level 
of statistical significance: ***, p < 0.0001; according to two-way ANOVA and posterior Bonferroni test.  
 
Owing to ambiguity concerning housekeeping genes and to avoid significant 
inaccuracies [103,104], we decided to confirm our results by repeating same Real-Time 
PCR using another housekeeping gene already optimized and available in our lab, the 
HPRT gene. 
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Similarly results and conclusions were obtained by using the HPRT housekeeping 
gene (Figure 33A and 33B). Thus, the non-expected results are not likely to be due to 
methodological problems.  
 
 
 
 
 
 
 
 
Figure 33. Real-Time PCR results for reanalysis of A- GRIM-19 and B- STAT3 in parental cell lines, 
Caki-2 and 786-O after 5Aza-dC treatment. Data is normalized for a standard curve and for endogenous 
gene HPRT expression. Results correspond to 3 experimental replicas. The error bars represent the mean 
± SEM (n = 3). The asterisks indicate the level of statistical significance: *, p < 0.05; ***, p < 0.0001; 
according to Student's t-test. 
 
 This data shows possible new insights of how GRIM-19 expression is downregulated 
in RCC and it will be an interesting focus of discussion. 
 
 4.3.3 Analysis of bisulfite conversion sequencing 
 Considering one part of the putative region of the GRIM-19 promoter, we decided to 
study in detail which CpG islands are effectively hypermethylated there. Bisulfite 
conversion and posterior sequencing were performed in four different fragments (see details 
Annex III). So far, we had reliable data concerning our fragment 3. This fragment comprises 
13 CpG islands from which we identified five that showed a relevant methylation status 
alteration (after bisulfite conversion, (after bisulfite conversion, the undermethylated 
cytosines will be converted into uracil; thus after sequencing it will appear as thymine). In 
figure 34 is shown an example of two out of the five CpG islands identified to be 
methylated (Annex V) in our tumoral cell lines (Caki-2 and 786-O) (in red, see Annex III).  
Interestingly, performing bisulfite conversion of samples treated with 5µM of 5Aza-dC, it 
was confirmed that those CpG islands become less methylated. A noteworthy fact is that, 
A B 
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apparently, Caki-2 is more methylated than 786-O. Considering the given example, we 
could see that in the Caki-2 cell line, treatment with 5µM of 5Aza-dC induced a drastic 
reduction of G’s picks (indicated by red arrows) which correspond to methylated C’s ( 
reverse primer used for sequencing of fragment 3). A different approach needs to be 
performed in order to quantify the effective difference in methylation levels between those 
cell lines, in order to confirm GRIM-19 expression pattern is different due to a 
hypermethylation of gene promoter. Eventually, a probe-based real-time PCR chemistry for 
methylation analysis (like EpiTect MethyLight Assays) would be a useful method for 
sensitive quantification of the methylation pattern. 
 
Figure 34. Bisulfite sequencing results obtained for two out of 13 CpG islands that comprise fragment 
three of our putative region of the GRIM-19 promoter. 
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5.1 Discussion 
Currently, metabolic stress is established as a hallmark of cancers [1] that deserves 
deeper understanding because of its promising contribution to antineoplastic therapeutic 
approaches and prevention. In particular, mitochondrial metabolism has shown evidences to 
be an important target to understand cancer etiopatogenesis [38, 39].On the other hand, 
GRIM-19 was identified by Angell et al. [34] as being associated with the IFN/RA-induced 
cell death [34]. Since its discovery, several works have been supporting its tumor 
suppressor role with a dual function: as part of MRC, being a complex I subunit and as 
participating in IFN/RA induced mortality [48-50].  
Regarding thyroid and kidney cancer, GRIM-19 has been proposed to have a critical 
involvement in the genesis of these type of tumors. Since the study by Máximo et al. [38] 
where mutations in GRIM-19 gene were found to be exclusively associated with 
mitochondrion-rich tumors of thyroid (oncocytomas), it was suggested that these alterations 
associated could be an explanation for this accumulation of mitochondria, as a 
compensatory mechanism. However, the results of Alchanati et al. [39] and a   recent work 
from our group (unpublished data) did not find GRIM-19 alterations or downregulation in 
renal oncocytic tumors. In renal cancer, GRIM-19 expression is absent or downregulated in 
the majority of the histotypes, particularly in ccRCC. Therefore, further investigation about 
the mechanism by which GRIM-19 is downregulated is required. The inhibition of 
transcription or epigenetic mechanisms (e.g. hypermethylation of the promoter) are pointed 
out as hypotheses that should be tested.  
To date, several studies have shown that GRIM-19 interaction with STAT3 protein is 
relevant in tumor progression [40-45]. Additionally, recent findings describe that STAT3 
also seems to regulate mitochondrial metabolic function, but further studies are required to 
disclose how both proteins may be involved in the mitochondrial metabolic shift [46, 47]. 
Taking all of this into account, we develop a study whose main goal was to 
understand the role of GRIM-19 in renal tumorigenesis and the way GRIM-19 interacts 
with STAT3. Our principal strategy consisted in blocking GRIM-19 expression using a 
specific shRNA in clear cell renal cell carcinoma cell lines (Caki-2 and 786-O) and human 
embryonic kidney cell line (HEK-293), in order to compare the results observed in a 
tumoral (Caki-2 and 786-O) and a non-tumoral (HEK 293) renal cell line. 
 Our results point to an important role of GRIM-19 downregulation in mitochondrial 
OXPHOS function, raise evidences of a metabolic shift towards a more glycolic profile, 
reflect a possible effect of GRIM-19 in STAT3 activity in RCC and raise an hypothesis of 
the mechanism by which GRIM-19 expression is regulated in RCC. 
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Consistent with the findings of Alchanati and colleagues [39] showing  that clear cell 
renal cell carcinoma (ccRCC) is the histotype that presents higher downregulation of 
GRIM-19 and it is also the most common histological subtype of renal cell carcinomas [78], 
similar conclusions were obtained in a series of kidney tumors studied in our group 
(unpublished data).   
Our initial findings on two ccRCC-derived cell lines - Caki-2 and 786-O revealed that 
the 786-O had a lower expression of GRIM-19 protein than the Caki-2 cell line. This 
difference was not due to mutations in the GRIM-19 gene, since sequencing of the 5 exons 
and exon-intron boundaries revealed WT DNA sequence; furthermore, we found no 
evidence for alternative splicing in the 786-O cell line, as proposed by He and Cao [102], 
but a normal transcript from exon 1 to 5 with 492bp.  
Additionally, by performing Real-time PCR, we observed that effectively Caki-2 
presents relative higher levels of GRIM-19 mRNA than 786-O cell line. Our result thus 
corroborate those of Alchanati and colleagues [39] that downregulation of GRIM-19 protein 
is not due to genetic mutations; it was also proved that, at least in our model, alterations at 
mRNA level are not the main cause. 
Taking into account several studies that found that tumor suppressor genes, in renal 
cell tumors, are downregulated by hypermethylation of the promoter [95-96], we analyzed 
the methylation status of a putative promoter region of GRIM-19 gene in Caki-2 and 786-O 
in order to ascertain whether the differences in GRIM-19 expression are caused by 
differential promoter methylation. Interestingly, 786-O, the cell line with lower GRIM-19 
expression, also presented higher levels of methylation than the Caki-2 cell line. Upon 
treatment with a DNA demethylation agent, 5Aza-dC, we could demonstrate a more 
significant decrease of demethylation status in 786-O cell line than in Caki-2. Therefore, the 
next step was to confirm if promoter demethylation (with 5Aza-dC) induced an increase of 
GRIM-19 expression. Surprisingly, an initial evaluation, showed that, after 5Aza-dC 
treatment, GRIM-19 protein expression was not affected in 786-O cell line, while in Caki-2 
cell line, GRIM-19 had a significant reduction of expression (data not shown). The 
quantification of GRIM-19 mRNA was performed by Real-time PCR and the results 
corroborated the analysis at protein level: after demethylation treatment Caki-2 cell line 
showed a statistically significant decline of GRIM-19 expression (approximately 50% 
reduction), whereas 786-O did not show any differences.  At same time, we also observed 
that STAT3 protein expression and activation levels were substantially higher after 5Aza-
dC treatment, particularly in 786-O cell line (data not shown). To eliminate any doubts, we 
confirmed those observations, by Real-time PCR. 
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In an attempt to deeper analyze the causes for this deregulation of GRIM-19 
expression, we tried to find how many and what were the CpG islands, in the fragment 
analyzed that were methylated. Reliable data was obtained in one out of our four fragments 
analyzed. We observed a distinct pattern of methylation between Caki-2 and 786-O cell 
lines: Caki-2 demonstrated to have CpG islands with elevated levels of methylation which 
effectively declined after 5Aza-dC treatment, while the 786-O did not show alterations in 
methylation pattern of same CpG islands. However, we did not use a quantitative method of 
methylation level. Overall, these observations may help explaining the non-expectable 
results from Real-time data because demethylation treatment was not efficient in 786-O cell 
line, CpG islands did not change their methylation status thus it support the fact we did not 
see any alteration at GRIM-19 expression level. Overall, the results show evidences that 
hypermethylation is affecting GRIM-19 gene expression.  
According to our results, the 786-O cell line shows low GRIM-19 expression and 
high promoter methylation, whereas the Caki-2 cell line shows high GRIM-19 expression 
and low promoter methylation. The unexpected results come from the 5Aza-dC treatment: 
while it does not affect GRIM-19 expression in 786-O cells, it leads to a reduction of 
approximately 50% in GRIM-19 expression in Caki-2 cells. 
Moreover, the 5Aza-dC treatment resulted in an increase of STAT3 levels. Our 
interpretation is that GRIM-19 gene expression is under regulation of a repressive 
mechanism by transcription factors (TFs). In this way, after demethylation with 5Aza-dC, 
compact chromatin opens, allowing access of TFs to sites in GRIM-19 promoter region 
(Figure 35) blocking in this way GRIM-19 transcription. This is supported by the fact that 
STAT3 mRNA levels are higher in 786-O cell line, the cell line that did not show 
significant alterations of its methylated CpG islands and so, its chromatin is probably 
maintained in its compact conformation. Therefore, we did not observe GRIM-19 
expression alterations (decrease or increase). Moreover, once there are several TFs that bind 
to GRIM-19 promoter region (Figure 35), not only STAT3 but most other TFs transcription 
factors could be involved in gene silencing. 
There are still other possible epigenetic events like histone deacetylation (usually 
responsible for compact chromatin conformation) that could be on the basis of GRIM-19 
downregulation.  An example comes from a breast cancer study that involved cancer 
therapy of 16 patients treated with a demethylating agent (hydralazine) and a histone 
deacetylase inhibitor (magnesium valporate) which was able to up- or downregulate at least 
3-fold, 1091 and 89 genes, respectively. GRIM-19 (or NDUFA13) was one of the genes that 
were upregulated, about 8-fold, after the treatment [105]. 
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Overall, these results provide us some insights of how GRIM-19 expression may be 
regulated in renal cell carcinoma.  The mapping of GRIM-19 promoter sequence is still 
required to eliminate any ambiguity, not just from actual data of this study but also from the 
published ones.   
 
 
Figure 35. The putative region of GRIM-19 promoter and the several growth factors that potentially 
binds to control this transcription region. 
 
In addition to the previous determinant question concerning how GRIM-19 
expression is regulated in renal cell tumors, the second part of this discussion is related with 
GRIM-19 role as a tumor suppressor gene, namely through its involvement in cell 
metabolism and in renal tumorigenesis. Preliminary data from our group made us 
hypothesize that GRIM-19 downregulation relates to the metabolic shift which confers the 
cells increased tumorigenic properties and our results support this assumption. The 786-O 
shGRIM-19 clones revealed an increase of glucose uptake and a consequent enhanced 
lactate production, showing also higher levels of glycolytic proteins (HK II and GLUT1). 
Nevertheless, the same was not true concerning the GRIM-19 downregulation in HEK cell 
lines. In an earlier study from our group, GRIM-19 silencing in HEK 293 cell line, resulted 
in a metabolic shift as seen by upregulation of glycolytic proteins. However, we observed 
that in comparison with parental HEK 293 cell line, HEK Ti89 clone showed significantly 
lower lactate production than parental HEK 293 cells, while glucose consumption was 
increased but not significantly. This could mean that lactate is being used to fuel 
mitochondria OXPHOS, as proposed by some authors [7]. Considering that HEK Ti89 has a 
non-tumoral background we could argue that its mitochondrial OXPHOS is more efficient; 
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in this way, in aerobic conditions they are capable to use lactate, as their main fuel, in 
contrast with 786-O shGRIM-19 clones that are derived from cells which preferentially 
obtain energy by aerobic glycolysis  (consume of glucose and production of lactate). 
These results suggest that GRIM-19 downregulation has a distinct metabolic effect in 
cells with tumoral or non-tumoral background. 
Considering the HEK non-expectable results, it would be interesting to further 
analyze whether a lower production of lactate and a lower expression of glycolytic proteins 
are somehow linked.  
Some authors describe a “metabolic symbiosis” between hypoxic and aerobic cancer 
cells [7]. It assumes that some cells use the excess lactate rather than glucose as source to 
energy production (ATP) by mitochondrial OXPHOS [7]. Furthermore, it is now known 
that in addition to cell membranes, mitochondria could also contain monocarboxylate 
transporters (mMCT) and lactic dehydrogenase (mLDH). Therefore, lactate flux regulation 
probably involves mitochondrial monocarboxylate uptake and oxidation. This is supported 
by a modification of “lactate shuttle” hypothesis which now includes also an intracellular 
lactate shuttle involving cytosolic to mitochondrial exchange [106]. To verify if this 
hypothesis is valid in our model, we should perform a Western blot analysis by incubating 
lysates from those cells with MCT antibody and see whether HEK Ti89 expresses more 
lactate transporter than scrambled and parental. Oxygen consumption of each cell line 
should be measured. 
The non-expectable glycolytic protein expression in HEK Ti89 is probably not related 
with its non-tumoral background because results are very distinct in comparison to HEK 
parental and scrambled cell lines.  
Another interesting aspect was that one of the clones of 786-O shGRIM-19 (90B) 
showed evidences of GLUT1 glycosylation, since the band corresponding to this transporter 
displayed a higher molecular mass, which is compatible with this post-translational 
modification. Past studies [107] had already shown that GLUT1had increased glycosylation 
in tumorigenic hybrids when compared with their parental tumor cells and that the 
regulation of glucose uptake by GLUT1 is influenced by its glycosylation modifications 
[108].These observations, indicate that this clone in particular may have increased glucose 
uptake through increased GLUT1 glycosylation.  
We found that GLUT1 was mainly localized to mitochondria, a finding already 
reported in other studies; still, the cause and the reason for that is not clear. So far, a study 
that analyzed GLUT1 immunoexpression in malignant tumors of various origins and 
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locations, found that GLUT1 is mainly located at cell membrane but also in cytoplasm (in 
all adenocarcinomas studied, including thyroid) [109].  
On the other hand, this localization may suggest that GLUT1 has a mitochondria 
protective role as shown by some studies [110]. Indeed, GLUT1 presence in mitochondria 
membrane seems to be essential to restore vitamin C, which is taken up in its oxidized form 
(DHA), followed by a reduction and accumulation as mitochondrial AA (mt AA). This has 
been considered a protective mechanism that avoids damage to the mitochondrial genome 
and membrane. Moreover, it was shown that GLUT1 is capable of mitochondrial import in 
human cells and that N terminus of GLUT1 functions as a mitochondrial targeting sequence 
[110]. In this regard, we could postulate that altering mitochondrial OXPHOS by GRIM-19 
downregulation could induce a non-explored protective mechanism of mitochondrial 
oxidative injury that may involve this observed translocation of GLUT1 to mitochondria. 
However, independently of activation and expression of GLUT1, we found this GLUT1 
localization in all cell lines (parental, scrambled and shGRIM-19 clones).  
We have also found that knockdown of GRIM-19 by shRNA implies a decrease of 
mitochondrial membrane potential (p<0.05) showing that it effectively interferes with 
complex I function and consequently, induces a mitochondrial OXPHOS failure. Moreover, 
we observed that shGRIM-19 clones are not so affected as scrambled or parental cell lines 
by either FCCP (uncoupler of OXPHOS) or 20µM rotenone (MRC complex I inhibitor) 
treatment. This probably reflects that ΔΨm of shGRIM-19 clones are already low. This 
corroborates another study which had demonstrated that specifically GRIM-19 
(NDUFA13), and no other subunits of complex I, is required for electron transfer activity of 
this MRC complex [51]. Furthermore, hyperpolarization (increase of ΔΨm) observable 
during treatment with lower concentrations of rotenone was not surprisingly as it reinforce 
previous results reported by our group [111]. Our group has reported a dual effect on the 
ΔΨm: a gain of ΔΨm has shown to be associated with a stimulation of mitochondrial 
biogenesis and morphological reorganization but integrity of mitochondria were unaltered 
and we did not observe release of cytochrome c (cyt c) to cytoplasm.  
Notably, Lu and Cao concluded that a dominant negative GRIM-19 mutant generated 
a disruption of ΔΨm but it also did not induce cytochrome c release; however, it sensitizes 
cells to undergo apoptosis [51]. 
In present study, preliminary data from immunofluorescence assay (Figure 19) shown 
a certain degree of mitochondrial fragmentation that needs to be confirmed; it must be 
evaluated if it is be associated or not with cyt c release and apoptosis. Indeed, the 
association of cyt c release and apoptosis with loss of ΔΨm is still a controversial issue. The 
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ΔΨm evaluation must be confirmed later using for example, TMRE staining following 
FACS (fluorescence- activated cell sorting) analysis and additionally, analyze cyt c release 
by Western blot. Results from this analysis could confirm if our model of study also shows 
evidences of a GRIM-19 and p-STAT3Ser727 link with necroptosis as recently reported 
[112].  
Last but not least, GRIM-19 has been described to be involved in regulation of cell 
adhesion, motility and invasion. Even though we did not address these issues, they are 
important aspects that might be related with some observations taken while we were 
performing this study. For instance, it is described that GRIM-19 regulates tumor cell 
invasion, by modulating EMT (epithelial-mesenchymal transition) and contact inhibition 
between cells (a typical process controlling cell division and cell growth). It was found that 
GRIM-19 depletion enhances adhesive and invasive potential of tumor cells [74, 113]. We 
also have some clues that this also occurs when inducing knockdown of GRIM-19 in HEK 
293 cell line. Taken into account that HEK Ti89 cells are more spread in contrast with 
scrambled and parental, it might be due to this loss of contact inhibition modulated by 
GRIM-19 thus, leading to a more invasive phenotype. 
Lastly, there is another mechanism by which GRIM-19 and, its well-known 
interacting protein, STAT3 may regulate cell adhesion and motility which is regulation of 
tubulin polymerization. GRIM-19 overexpression blocks cell motility by decreasing tubulin 
polymerization mainly by inhibiting STAT3 (antagonist of depolymerization activity of 
stathmin) and Src inhibition [74,114]. It might explain why in our model, cells that have 
significantly higher levels of GRIM-19 shown a visible distinct pattern of cytoskeleton 
organization (microtubules are not so well organized and cells are smaller) as elucidated in 
figure 36. 
 
Figure 36. Schematic representation of cellular role of GRIM-19 in cell motility and in cytoskeleton 
structure (adapted from [114]).  
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Regarding the GRIM-19 and STAT3 interaction, several studies demonstrate that 
GRIM-19 downregulation leads to an increase of both STAT3 expression and activation of 
its role as transcription factor by enhancing expression genes involved cell proliferation and 
also antiapoptotic proteins [60]. After controversial questions about how those two proteins 
interact, a study came out showing that a particular motif is essential for their interaction 
[53]. Nevertheless, there are new evidences that STAT3 has also some mitochondrial 
function rather than just acting as a nuclear transcription factor [47].  On the other hand, 
there are also some evidences that STAT3 has an important role in renal tumorigenesis but 
its activation in renal tumor remains to be clarified [93]. With this work, we also looked for 
the impact of shRNA of GRIM-19 in the expression and activation of STAT3. Ideally, we 
tried to understand this effect in tumoral and non-tumoral scenarios, by using 786-O and 
HEK293 cell lines, respectively. 
If initially we started by seeing that effectively downregulation of GRIM-19 shows an 
increase of STAT3 expression and also activation then, in an attempt to replicate those 
results, we found different observations. Cell culture conditions demonstrated to affect the 
efficiency of knockdown of GRIM-19 by shRNA. However, both analysis have in common 
that GRIM-19 downregulation enhances STAT3 activity as we could observe an increase of 
STAT3 phosphorylated forms (p-STAT3Try705 and p-STAT3Ser727, its active forms). In 
contrast, in our non-tumoral model (HEK 293), we observed absence of p-STAT3Try705 
expression and the clone with shGRIM-19 (HEK Ti89) shown lower expression of p-
STAT3Ser727.  Those results suggest a different effect of GRIM-19 and STAT3 interaction 
in a tumoral and non-tumoral scenarios.  
Additionally, regarding kidney tumorigenesis, preliminary data from our group 
support a particular interaction between GRIM-19 and p-STAT3Ser727.  
So far,  in vitro results from our group showed that p-STAT3 Ser727 is present in the 
cytoplasm co-localized with GRIM-19 in mitochondria, confirming the mitochondrial 
location of p-STAT3 Ser727 (Figure 37 – unpublished data). In addition, 
immunohistochemistry analysis in a series of kidney tumors also found that the main 
location of p-STAT3 Ser727 is in the cytoplasm, most probably in mitochondria [49]. 
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Figure 37. GRIM-19 and p-STAT3 Ser727, but not pSTAT3 Tyr705 co-localizes in mitochondria as 
observed by merged pictures from GRIM-19 and p-STAT3 Ser727 immunocytochemistry stain for each 
one (unpublished data). 
 
The data from cell fractionation assay performed in this study, provided some 
observations which maybe complement those previously obtained by our group.  
From this experiment, in agreement with literature [49, 51], we could confirm GRIM-
19 location in the mitochondria, in both scenarios, in tumoral and non-tumoral cell lines. 
Concerning STAT3 protein we had indirect evidence that p-STAT3 Ser727, like GRIM-19 
protein, is also located at mitochondria. These evidences point to the fact that GRIM-19 and 
STAT3 maybe interact at the mitochondrial level as their co-localization was also clearly 
observed in other models [115]. Despite this analysis of protein expression could only be 
qualitative, this result should be proved and an alternative could be immunoprecipitation 
analysis which has an advantage to give reliable information about protein interaction. A 
study of co-localization by immunofluorescence, as exemplified in figure 37, could also be 
done but in most of the cases, it has a disadvantage to imply several optimizations. In 
addition, going a bit further, it will be even more interesting to clarify if phosphorylation of 
Ser727 and of Tyr705 in STAT3 has an independent role in kidney tumorigenesis, 
concerning their cellular localization, once it was already observed in some preliminary data 
by IHC technique in our group. Are they present in the same molecule or can be present in 
different molecules, activating them independently? This might be assessed by performing a 
Proximity Ligation Assay (PLA) technique. 
If we postulate that the phosphorylation occurs in different molecules they might have 
a different interaction with GRIM-19, explaining also their cellular localization. 
Probably, GRIM-19 in cytosol is related with p-STAT3Tyr705 in connection with 
GRIM-19 cell death role by inhibiting STAT3 translocation to the nucleus and 
consequently, its transcriptional activity. On the other hand, GRIM-19 and p-STAT3Ser727 
localization in mitochondria seems to be both essential to maintain mitochondrial OXPHOS 
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and probably, also for some mitochondria role in apoptosis. The latter is supported by 
GRIM-19 as a subunit of complex I and STAT3 role to maintain complex I and II activity. 
Additionally, GRIM-19 and p-STAT3Ser727 interaction has being recently connected with 
increase of cell death mechanism but it still needs to be confirmed. In that sense we propose 
a possible interaction which is depicted and summarized in figure 38.  
If STAT3 is localized in mitochondria it may respond to cytokines, thus coordinating 
energy production by mitochondria. Such discovery should lead to a reassessment of several 
pathways involved in tumorigenesis. However, there is still a problem to solve which is a 
consensual STAT3 mitochondria localization and its role in regulation of ATP generation. 
To the best of our knowledge there is at least one report which did not detect STAT3 in 
heart mitochondria contrarily to the robust findings shown by Wegrzyn et al. [47] and in 
several other models [75,76 ] . The reasons of this discrepancy are not clear, but might be 
due to the fact that there is not a 1:1 stoichiometry between STAT3 and other components 
of complex I in the mitochondria. Indeed, a study by Phillips and collaborators reported that 
the cellular ratio of Complexes I/II to STAT3 is not 1:1, but rather 105 to one. It means that 
there are not enough STAT3 molecules per mitochondrion which implies that STAT3 was 
not modulating cardiac ATP generation via direct protein-protein interaction with the 
complexes of OXPHOS [116]. Therefore, STAT3 mitochondrial function may result instead 
from other undefined cooperative mechanisms that deserve further investigation.  
 Even though our postulated model may show some weaknesses, we think that it is 
still a conceivable hypothesis that should to be deeper analyzed. 
 
Figure 38. Our proposed model of GRIM-19 interaction with STAT3 phosphorylated isoforms 
(adapted from [117]). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSIONS and FUTURE 
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6.1 Conclusions  
GRIM-19 is novel tumor suppressor gene that it has been shown to be downregulated 
in all subtypes of renal cell carcinoma (RCC); thus, it is a good candidate to study 
etiopathogenesis of RCC. 
The present in vitro study was performed using cell lines derived from ccRCC, as a 
model, which allow us to get the following major conclusions:  
  GRIM-19 downregulation in ccRCC are not due to gene mutations or alterations at 
transcriptional level. 
 
 ccRCC cell lines with different expression of GRIM-19 protein shown differences 
concerning the methylation status of a putative GRIM-19 gene promoter region. 
 
 Although GRIM-19 gene promoter was found to be methylated, this did not 
represent a direct cause of GRIM-19 downregulation in ccRCC. 
 
 We provided, for the first time, evidence that GRIM-19 expression could be 
regulated by a repressive mechanism, through the action of transcription factors. 
 
 
 Knockdown of GRIM-19 expression by shRNA enhance a metabolic shift in 
tumoral cells, it means that they became more glycolytic, but it was not observed in 
non-tumoral cells.  
 
 We confirm the localization of GRIM-19 in mitochondria which suggests its 
biological roles are likely to be based on its mitochondrial function, in ccRCC. 
 
 Our data suggests that GRIM-19 plays an important role in cell morphology, 
mitochondrial reorganization and promotes cellular invasive properties. 
 
 We provided insights into a transcription-independent mechanism whereby 
mitochondria localized STAT3 might be involved in renal cell tumorigenesis. 
 
 We showed that GRIM-19 regulates STAT3 phosphorylated forms. 
 
 Regarding the relationship between the GRIM-19 and the STAT3 phosphorylations, 
our data suggest a mitochondrial localization p-STAT3 Ser727 where it might 
interact with GRIM-19. 
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Although several studies performed in recent years concerning the role of GRIM-19 
protein, it remains a challenge to understand the different functions of GRIM-19 in cellular 
biology and in oncobiology. Likewise, throughout this work several questions/hypothesis 
were raised concerning GRIM-19 and its related molecules. 
Collectively, our results suggest that GRIM-19 has a broad role in ccRCC 
tumorigenesis and we provide evidences that it is a topic that deserves deeper understanding 
due to its promising contribution to antineoplastic therapeutic.  
 
 
 
6.2 Future perspectives 
While we were performing the work presented in this thesis, several questions were 
raised concerning validations and complementary work that would be important to carry out 
to clarify some issues. The work that we would like to pursue in the future in order to 
address such questions is:  
  In order to confirm methylation status of Caki-2 and 786-O, we should perform a 
method for sensitive quantification of the methylation pattern like a probe-based real-
time PCR chemistry for methylation analysis (like EpiTect MethyLight Assays). 
 
 Concerning the mechanism by which GRIM-19 expression is regulated in ccRCC, we 
can start by testing whether STAT3 is one of the transcription factors responsible for 
a possible repression of GRIM-19 gene transcription. This might be assessed by 
constructing a luciferase report vector with GRIM-19 promoter gene. Also, by 
performing STAT3 downregulation (by shRNA, for example) we would be able to 
confirm or exclude this hypothesis. 
 
 It would be interesting to analyze if downregulation of GRIM-19 expression observed 
in ccRCC could be regulated by histone modifications (eg.  deacetylation). To 
accomplish that we could treat cell lines with a histone deacetylase inhibitor (to allow 
open chromatin conformation and gene transcription) and then confirm GRIM-19 
expression, both at the mRNA and protein level. 
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 The lack of replicates in cellular growth and cell death by BrdU and TUNEL assays, 
respectively, should also be filled. It will be very important to confirm that GRIM-19 
knockdown induce cell proliferation and/or apoptosis. In order to obtain a reliable 
data, BrdU staining followed by flow cytometry should be a better approach instead 
of fluorescence microscopy analysis. 
 
 It remained to be elucidated whether and how depletion of GRIM-19 would affect 
cell motility, migration and invasion. These features should be analyzed by 
conventional techniques such as wound closure assay (analysis in a Time-lapse 
microscope) and matrigel invasion assay, respectively. 
 
 Given the evidence for mitochondrial fragmentation in our data, it is important to 
know whether somehow this is linked with an increase of cell death. Thereby, ΔΨm 
evaluation must be confirmed for example by TMRE staining following FACS 
(fluorescence- activated cell sorting) analysis as well as analysis of cyt c release by 
Western blot. Moreover, these experiments could confirm some recent evidence of a 
GRIM-19 and p-STAT3Ser727 link with necroptosis.  
 
 Our renal tumor cells confirmed our assumption that knockdown of GRIM-19 leads 
to a metabolic shift conferring cells a more glycolytic profile; by contrast, in HEK 
cell lines, we did not observe some consequences which may be explained by its non-
tumoral properties. However, to confirm the GRIM-19 involvement in a metabolic 
shift and demonstrate that it confers the cells tumorigenic properties, the glycolysis 
and OXPHOS status of all cell lines must be assessed by measuring their oxygen 
consumption levels. 
 
 Although we have clues regarding GRIM-19 and p-STAT3 Ser727 interaction in 
mitochondria, this needs to be proved as well as their cellular co-localization. In this 
regard, through immunoprecipitation analysis, we could understand if these proteins 
interact; to confirm if they co-localize in mitochondria, we suggest perform an 
immunofluorescence analysis. 
 
 Since GRIM-19 is downregulated in renal cell tumors and STAT3 seems to be 
required for OXPHOS and as shown by other studies (we also observed STAT3 
located at mitochondria), it will be interesting to analyze whether STAT3 could be 
confined to mitochondria as a compensation for lack of GRIM-19 and complex I 
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impairment.  To clarify this, a shRNA of STAT3 could be done and see if it induces a 
disruption in OXPHOS. The use of a STAT3 inhibitor might be an alternative. To 
clarify the impact of those strategies particularly in MRC complex I, we should 
measure complex I activity. 
 
 Together these are only some of the experiments that could be useful to perform, in 
order to clarify some interesting aspects observed during this study and to prove some of 
our hypotheses.  
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Annex I – Amplification of GRIM-19 gene 
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 GRIM-19 gene sequence and primers 
 
 
  
 
 
Annex II- Methylation status analysis 
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 EpiTect Methyl qPCR assay: principle and procedure 
 
 ΔCT data analysis 
If ΔCT (Ms – Mo)> 1.0 and ΔCT  (Md – Mo) > 1.0, use following formula to calculate the 
fraction of hypermethylated DNA 
 
 Unmethylated (UM) DNA fraction: 
FUM= 2^ - (Ct Md) / (2^ (- Ct Mo) – 2^ (- Ct Msd) ) 
 Hypermethylated ( HM) DNA fraction: 
FHM= 1- FUM 
 DNA copies resistant (R) to enzyme digestion (should be < 25%): 
FR= 2 ^ - (Ct Msd - Ct Mo) 
  
 
 
Annex III- The putative GRIM-19 promoter region  
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 CpG islands methylated– analyzed in four separated fragments  
 
TGTTTAGGTTTGGGTAGTTATGGGTTTGGCGGTCGAAGTCGAAGTCGGTGAGTTTGACGCGGCGTTCGTT
CGGGTTTAGTAGTACGTTTTCGTATTTGAGGTCGCGGTGTATTAGGTGATGATCGTGTAGGTAGCGTACG
GCGTCGGCGATTTGCGTAAAGAGGTCGCGCGTTTGAATTTCGGGGATGCGTTCGTTGCGTTGTACGGTTT
GTAGTAGGTCGGTGGCGGTCGTTTTTATTACGATGTATAGTTTTTCGTTGTATATTTCGATGAATTCGAA
GACGTGTACGATGTGCGGGTGTCGTACGTTTCGTAGGATGGATAGTTTTCGCGGTAGGAATTTGTTGACG
AAGTTCGGGGGCGTTCGTCGTCGGTTTATTATTTTGATGGTTACGGTATTTTTGTATTTTTTGGATGTGG
TTATTTTTATTTTGGAGTAGTTGTTTTTTTTAATTGTGCGGTTTAGTTTATAATCGAGTTCGTTTAGAAG
TTTGTTTTTCGATATGGTGGCGTTTAGGGCGTACGGGGGGTAGGAGGCGGTTGTTGTCGGGGGGCGGTCG
GATTTTAATTTCGGGTTTAAGTTATGGCGTTTGGTATTTATATTTTCGTATTTTTATGTGTTTATTGTTA
GATATTGGTCGTTGTTGTGTTTTTTATTGTTTCGTAATAATTTTTGTTTTGTGAAGTGATTGCGGGCGTT
ATTTCGTTTTAGGGTGGGGGTTCGGGATTTCGTTTCGGGGTTATTTTAGTTTTTTTGTTTTGTGATTTAT
AATTATTTTGAATGGTTAGTTTTCGATGAGAGGTTATTAGTAAGGGATATTTATTATTATTAGGGAGTAG
AATTCGTTTTAGGGATTGGGGTGAGTTCGATTTCGAGTAGTAGTTGTTTTTTAATATTATGTATTTAGTT
CGTGATTACGTGGAGTTTTGGGTTTCGCGTAGAGTTTTTAGACGGGGCGAAAACGGGAAAAGGGGTTTTA
ATTGGGGTATTTGGTTTTTTTGAGAGTTCGGAGTTTTTGATTGGTTTGCGTAATATTTTAGAGGTAAGGT
GAACGCGAGGGTTTATAATGTAAGAATTAAGGCGAGTTACGTTTTGTTTGGGTAAAAGAGGAGTAAAGAT
TTTTTAGTTGTAGTTCGGTAGCGTATTTTTATTTAGGGTTCGTCGTTAGAGTTTTTTCGCGCGGTCGGAT
AGTTATATTATTGTTCGGGATTTTTTAGTCGTGTCGCGGATTATTTTAAGTGTTTTTGTTATATTTATTA
TGGCGGTGGTAGTAAGTTATTTTCGTTCGGGATCGGAAGTGTGGGATATTGCGAGTATGGCGGCGTTAAA
GGTGAAGTAGGATATGTTTTCGTCGGGGGGTTATGGGTTTATCGATTATAAACGGAATTTGTCGCGTCGA
GGATTGTCGGGTTAGTATTATTTTGTGTTGGGGTTTTAGAGTTTGGGTATTTGGGGTTTGGGGGTGGGGT
TTTGGGGATATAGGTGG 
 
 
XXX- CpG islands 
XXX- GRIM-19 Exon1 
XXX- initiation codon ATG 
Figure A5.1- The putative region of GRIM-19 promoter whose sequence shown was converted to 
perform bisulfite analysis and sequencing. Primers of fragment 3 (Grim19_MET_Prom-3F and respective 
3R) are depicted in blue. Depicted in red are identified the 1st and 2nd CpG islands whose analysis shown 
in RESULTS- 4.3.3. Additional four CpG islands found to be methylated: 3rd and 4th CpG islands- 
localization depicted in green; 5th CpG island- localization depicted in purple.  
 
 
XXX- primers fragment 1F, 1R/2F 
XXX- primers fragment 3F/2R, 3R/4F 
XXX- primers fragment 4R 
  
 
 
 Annex IV- BrdU and TUNEL assays  
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  Evaluation of cell proliferation and cell death  
 
 
 
Figure A4.1- Analysis of cell proliferation (BrdU) and cell death (TUNEL) of parental cell lines 
Caki-2 and 786-O and shGRIM-19 clones. 
 
 
 
 
 
 
 
 
 
Figure A4.2- Analysis of cell proliferation (BrdU) and cell death (TUNEL) of HEK 293 cell line, 
scrambled ( HEK TR2) and shGRIM-19 clones (HEKTi89) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 Annex V- Bisulfite conversion and sequencing analysis 
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 Additional data about analysis of methylation status of CpG islands in GRIM-
19 gene promoter 
 
 3rd and 4th CpG islands (localization depicted above in green )  
 
 
 
 
 
 
 
 
 
 
 5th CpG island ( localization depicted above in purple) 
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Normal DMSO 5µM 5Aza-dC 
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